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Abstract 
Osteoporosis is a major health problem in our aging society. This metabolic disease, which is characterized 
by a deterioration of the bone microarchitecture and a significant loss of bone mass, is affecting a rising 
number of mostly elderly patients. The main clinical consequences are typical fragility fractures resulting in 
severe pain, morbidity, and mortality for affected patients. Osteoporosis does not only cause fractures, but 
also complicates fracture treatment, as implants are difficult to anchor in the impaired bone structure. 
Therefore, many mechanical and pharmaceutical approaches have been developed over the last decades to 
target this issue and improve implant anchorage in osteoporotic bone.  
The overall goal of the present PhD thesis was the development of a bisphosphonate (BP) releasing 
hydrogel that can enhance implant fixation in osteoporotic bone. The project was divided into three major 
sections: the investigation of the BP effect on peri-implant bone, the development and testing of the drug 
delivering biomaterial, and the evaluation of its efficiency in terms of implant fixation improvement. An 
ovariectomized rat model of postmenopausal osteoporosis was utilized for the investigation of the spatio-
temporal effect of locally released Zoledronate, the BP used in this study. The drug was delivered from a 
biodegradable hyaluronic acid (HyA) hydrogel matrix to the bone stock surrounding screws that were 
implanted in the femoral condyles of the rats. Static and dynamic bone histomorphometric parameters 
were monitored in four concentric bone layers around the screw with time-lapsed in vivo microCT scans. 
With this study, we were able to demonstrate a significant enhancement of early bone formation rate 
accompanied by an efficient inhibition of peri-implant bone resorption in a large range around the screw. In 
a second in vivo study, we incorporated Zoledronate-loaded hydroxyapatite nanoparticles in the HyA 
hydrogel resulting in an unexpected rapid mineralization of the hydrogel within 10 days after implantation. 
Histology performed 2 months after implantation revealed granule-shaped mineralized spots within the 
peri-implant bone serving as scaffolds for new bone formation. When using Zoledronate-loaded particles, 
we could demonstrate a strong inhibitory effect on both peri-implant bone resorption and mineralized 
hydrogel degradation. Finally, we used the in vivo microCT scans of the first animal study to create micro-
finite element models for the analysis of the screw fixation time course. We were able to show that 
Zoledronate locally delivered from the hyaluronic acid hydrogel improved screw fixation significantly as 
soon as 17 days after implantation when compared to an untreated control group. This difference persisted 
until the end of the study at day 58.  
Taken together, the studies performed for the present PhD thesis demonstrated an excellent suitability of 
HyA hydrogels for the local delivery of BPs intended to improve implant fixation in impaired bone. A 
Zoledronate triggered enhancement of screw fixation occurred early and persisted over a prolonged period, 
x 
an important aspect considering that osteosynthesis implants need a reliable bone anchorage from the 
time of implantation until complete fracture healing. Furthermore, it could be shown that an addition of 
hydroxyapatite particles to the HyA resulted in a rapid in vivo mineralization of the hydrogel, a promising  
feature for bone defect repair applications. 
Keywords 
Bisphosphonate; drug delivery; hydrogel; hydroxyapatite; implant fixation; microCT; microFE; OVX rat 
model; dynamic histomorphometry 
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Zusammenfassung 
Die Skeletterkrankung Osteoporose ist ein ernsthaftes gesundheitliches Problem und betrifft aufgrund der 
aktuellen demographischen Entwicklung und der steigendenen Lebenserwartung immer mehr Menschen. 
Diese Krankheit manifestiert sich typischerweise in einer signifikanten Verminderung der Knochenmasse 
gepaart mit einer veränderten Knochenstruktur. Als Folge dieser Knochenschwächung treten Frakturen bei 
Betroffenen oft schon bei geringen Belastungen, wie zum Beispiel einem Sturz aus Standhöhe, auf. Diese 
Knochenbrüche resultieren bei den oft älteren Patienten nicht selten in dauerhaften Behinderungen, einer 
eingeschränkten Mobilität und einer verringerten Lebenserwartung. Die Osteoporoseerkrankung erhöht 
aber nicht nur des Frakturrisiko, sie erschwert nach Auftreten eines Knochenbruchs auch die chirurgische 
Versorgung. Üblicherweise verwendete Osteosynthese-Implantate können in der der geschwächten 
Knochenstruktur oft nicht zuverlässig verankert werden und dislokieren. In den letzten Jahrzehnten wurden 
daher zahlreiche mechanische und pharmakologische Ansätze zur Verbesserung der Implantatverankerung 
in osteoporotischen Knochen entwickelt und getestet.  
Das Ziel der vorliegenden Dotorarbeit war die Entwicklung eines Bisphosphonat-freisetzenden Hydrogels, 
das zur lokalen Verstärkung der Knochensubstanz in direkter Umgebung eines Implants eingesetzt werden 
kann. Das Projekt umfasste drei Hauptaufgabengebiete: Zunächst wurde der Einfluss des lokal applizierten 
Bisphosphonats auf den Knochen in Implantatnähe ermittelt. Danach wurde ein geeignetes System zur 
Freisetzung des Wirkstoffs entwickelt. In einem dritten Schritt wurde die Effizienz des gewählten Hydrogels 
bei der Verbesserung der Implantatverankerung getest. 
Für die in vivo Untersuchung der räumlich-zeitlichen Wirkung von lokal freigesetztem Zoledronat, dem für 
die vorliegende Arbeit verwendeten Bisphosphonat, wurden ovariektomierte Ratten als Modell für 
postmenopausale Osteoporose verwendet. Miniaturschrauben wurden in die Femurkondylen von Ratten 
implantiert und der Wirkstoff wurde dabei direkt mit einem Hyaluronsäure-Hydrogel in die Umgebung der 
Implantate eingebracht. Mit Hilfe von zeitversetzt erstellten MicroCT-Aufnahmen wurden die statischen 
und dynamischen Knochenparameter in vier konzentrisch um die Schraube angeordneten 
Knochenschichten ermittelt. In diesem Tierversuch konnte in den Zoledronat-behandelten Ratten im 
Vergleich zu den Kontrollratten eine deutlichen Zunahme der Knochenneubildung direkt nach 
Schraubenimplantation gepaart mit einer Verringerung der Knochenresorption während des ganzen 
Studienzeitraums beobachtet werden.  
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In einer zweiten in vivo Studie wurde der Wirkstoff vor Einbringung in das Hydrogel auf Hydroxyapatit-
Nanopartikel absorbiert. Die Präsenz der Keramikpartikel, sowohl mit als auch ohne Wirkstoff, resultierte in 
einer unerwarteten, innerhalb weniger Tage nach Einbringung erfolgenden in vivo Mineralisierung des 
Hydrogels. Histologische Untersuchungen, die 2 Monate nach implantation von Schrauben und Hydrogel 
erfolgten, zeigten granulatförmige mineralisierte Stellen eingebettet in neugebildeten Knochen. Bei 
gleichzeitiger Verwendung von Zoledronat und Hydroxyapatitpartikeln konnte ein starker inhibitorische 
Effekt sowohl auf die Knochenresorption als auf auch den Abbau des mineralisierten Biomaterials gezeigt 
werden. 
Im dritten Teil der Arbeit wurden die für den ersten Tierversuch erzeugten microCT Aufnahmen zur 
Erstellung von micro-Finite-Elemente Modellen verwendet. Diese Modelle dienten zur Untersuchung des 
zeitlichen Verlaufs der Schraubenverankerung im Rattenknochen. Es konnte gezeigt werden, dass die lokale 
Freisetzung von Zoledront aus einem Hyaluronsäure-Hydrogel schon nach 17 Tagen die Ausreissfestigkeit 
der Schrauben signifikant erhöht. Der Unterschied zwischen den mit Zoledronat behandelten und 
unbehandelten Tieren blieb die folgenden 6 Wochen bis zum Studienende bestehen. 
Zusammengefasst belegten die im Rahmen dieser Doktorarbeit durchgeführten Versuche die 
ausgezeichnete Eignung abbaubarer Hyaluronsäure-Hydrogele für die lokale Freisetzung von 
Bisphophonaten zum Zweck der Verbesserung der Implantatverankerung in osteoporotischem Knochen. Es 
konnte gezeigt werden, dass die lokale Appliakation von Zoledronat den Halt eines Implantats schnell und 
dauerhaft verbessern kann. Dies ist ein wichtiger Aspekt, da die Verankerung der zur Frakturbehandlung 
eingesetzten Osteosynthese-Implantate über den gesamten Zeitraum der Knochenheilung sichergestellt 
werden muss. Zusätzlich konnte gezeigt werden, dass die Zugabe von Hydroxyapatit-Partikeln zum 
Hyaluronsäure-Hydrogel in einer schnellen in vivo Mineralisierung der Gels resultiert. Dieses Ergebnis 
erweitert den Kreis der möglichen Anwendungsgebiete dieses Biomaterials auf die Reparatur von 
Knochendefekten. 
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 Introduction Chapter 1
 Bone 1.1
Bone is defined as “any piece of hard whitish tissue making up the skeleton in humans and other 
vertebrates” in the Oxford Dictionary. Despite its simple appearance, bone is a complex and dynamic living 
tissue that fulfills many functions in the human body. First, the 206 bones of an adult provide a structural 
framework for the body and attachment points for tendons and the skeletal muscles. The resulting leverage 
system allows us to move. Another important function of the bones is to support and protect the sensitive 
inner organs such as the brain and the heart. Apart from their mechanical and structural functions, bones 
are also involved in metabolic processes: they store and release important minerals such as calcium and 
phosphorus (mineral homeostasis). Furthermore, the red marrow of bone produces platelets and red and 
white blood while the yellow bone marrow is rich in adipose cells and stores triglycerides (Nordin 2012; 
Tortora 2013). 
1.1.1 Bone Structure 
Bone is characterized by a very specific structure that varies depending on its position and function. Two 
main structures can be distinguished: trabecular (cancellous) and cortical (compact) bone (Figure 1.1). 
Around 80% of the human skeleton is cortical bone and 20% is trabecular bone. Cortical bone is the 
strongest type of bone tissue and forms the shell for all bones. Additionally, it makes up the bulk of the 
diaphyses of long bones. Cortical bone is very dense and arranged in repeating structural units called 
osteons or haversian systems. Each osteon contains a longitudinal central haversian channel that houses 
blood vessels, nerves, or lymphatic vessels surrounded by concentrically arranged lamellae made of hard, 
calcified extracellular matrix. The tube-shaped osteons are bundled together longitudinally to the bone 
axis. The osteocytes (mature bone cells) in the cortical bone are interspersed between the osteons in 
structures called lacunae. These lacunae are connected via tiny fluid-filled canaliculi. This channel system 
ensures a nutrient supply for the osteocytes.  
In contrast to cortical bone, trabecular bone does not contain osteons. It is composed of irregular lattices 
of thin bone columns called trabeculae. The spaces between the trabeculae of most bones are filled with 
red bone marrow. The trabeculae themselves are composed of concentric lamellae, osteocytes lying in 
lacunae, and a canaliculi network. Trabecular bone is very light-weight compared to cortical bone and helps 
to reduce the overall weight of bone to facilitate body movements (Nordin 2012; Tortora 2013). The 
orientation of the trabeculae in trabecular bone is according to the “form follows function” principle 
(Stromsoe 2004). A dense fibrous membrane, called periosteum, surrounds all bones. This membrane, 
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which is highly permeated with nerves and blood vessels, is connected with the haversian channels of the 
cortex. A thinner membrane, called the endosteum, lines the marrow cavities of yellow fatty bone marrow 
(Nordin 2012). 
On a microscopic level, bone has two distinct states as it matures: woven bone and lamellar bone. Woven 
bone is immature bone and is found in fetuses, in newborns, in fracture calli, close to the growth plate of 
bones, and in certain bone diseases. Lamellar bone replaces the woven bone one month after birth, or after 
the remodeling process of a fracture callus (Nordin 2012). 
 
Figure 1.1:   Structure and composition of a typical long bone (adapted from 
http://classes.midlandstech.edu/carterp/Courses/bio210/chap06/lecture1.html). 
1.1.2 Bone Cells 
Bone as a connective tissue is composed from an extracellular matrix that surrounds widely separated cells. 
This extracellular matrix contains around 25% water, 25% type 1 collagen fibers, and 50% mineral 
crystallized salts (apatite) (Stromsoe 2004). The collagen is responsible for the tensile strength of bone and 
the mineral component is responsible for the compressive strength of bone. Four major cell types can be 
found in bone tissue. The first type is osteogenic cells, which are unspecialized mesenchymal stem cells and 
the only bone cells that undergo cell division. Osteogenic cells develop into osteoblasts, the second cell 
type, and are known to be responsible for bone formation. Osteoblasts are responsible for building the 
extracellular bone matrix by synthesis and secretion of collagen fibers and other organic components. This 
initially soft matrix, called osteoid, is later transformed into hard bone matrix via a mineralization process. 
Once the osteoblasts are surrounded by their matrix and become trapped, they change their form and 
function and become osteocytes, or mature bone cells. Osteocytes are the main cells in bone and they are 
responsible for metabolic functions such as the exchange of nutrients and waste with blood cells. 
Osteoblasts can also flatten and become lining cells, which cover and protect the bone surface (Boyce, 
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Rosenberg et al. 2012). The last group of important bone cells are osteoclasts. These huge, multinucleated 
cells are derived from a fusion of around 50 monocytes. Osteoclasts release lysosomal enzymes and acids 
that can digest the protein and mineral components of the bone extracellular matrix during the bone 
resorption process (Tortora 2013). 
1.1.3 Bone Modeling and Remodeling 
Two important processes, bone modeling and remodeling, ensure the development and maintenance of a 
vertebrate’s skeletal system (Raggatt and Partridge 2010). Bone modeling is required for the growth and 
adaption of the skeleton to mechanical loads. Modeling requires the osteoblast-mediated formation and 
osteoclast-mediated resorption of bone; these two processes occur independently at distinct anatomical 
sites (Raggatt and Partridge 2010). Bone remodeling, however, is needed for the removal and repair of old 
and damaged bone as well as for mineral homeostasis (Seeman 2009; Boyce, Rosenberg et al. 2012). For 
bone remodeling, resorption and formation occur sequentially and well-coordinated at the same location 
to preserve bone mass as much as possible (Raggatt and Partridge 2010). The bone remodeling process 
occurs over several weeks and is performed by clusters of osteoclasts and osteoblasts arranged in basic 
multicellular units (BMUs) (Figure 1.2) (Boyce, Rosenberg et al. 2012). An active BMU contains a leading 
front of bone-resorbing osteoclast that creates trenches in the bone surface (Raggatt and Partridge 2010; 
Boyce, Rosenberg et al. 2012). Reversal cells of unclear phenotype then cover the exposed bone surface 
and prepare it for the deposits of new bone. The tail portion of the BMU is occupied by osteoblasts that 
secret osteoid and later on direct the transfer of mineralized lamellar bone (Raggatt and Partridge 2010). 
Collagen type 1 fibers and other matrix-bound proteins such as growth factors are released during 
resorption and can influence the osteoblasts and cells in the bone marrow adjacent to the bone remodeling 
sites (Boyce, Rosenberg et al. 2012). 
 
Figure 1.2:   Bone remodeling process in a basic multicellular unit (BMU) (adapted from (Raisz 2005)). 
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1.1.4 Osteoporosis and Bone Loss 
An imbalance in bone formation and resorption compromises bone homeostasis and leads to an abnormal 
bone loss or, less frequently, bone gain. This loss of equilibrium occurs in many common bone diseases 
such as osteoporosis, osteopetrosis, hyperparathyroidism, renal osteodystrophy, Paget’s disease, and bone 
tumors (Cummings and Melton 2002). Osteoporosis is the most frequent bone metabolic disease and has 
existed throughout human history, but it has only recently been considered a major clinical problem due to 
increasing life expectancy in humans. This systemic disease is characterized by a loss of bone mass and a 
deterioration of the bone microarchitecture, resulting in bone fragility and susceptibility to fractures 
(Figure 1.3) (Stromsoe 2004). The world health organization (WHO) defined a diagnostic criterion for 
osteoporosis to be a bone mineral density (BMD) of at least 2.5 standard deviations lower than the average 
bone peak mass of a 30-year old individual of the same gender (Hernlund, Svedbom et al. 2013). Based on 
this criterion, approximately 22 million women and 5.5 million men between the ages of 50 to 84 were 
estimated to have osteoporosis in the EU in 2010. Due to the changes in population demography, the 
number of men and women with osteoporosis in the EU is expected to rise by 23% from 27.5 million in 
2010 to 33.9 million in 2025 (Hernlund, Svedbom et al. 2013).  
 
Figure 1.3:   Scanning electron microscope images of human 3
rd
 lumbar vertebrae with normal and osteoporotic bone 
microarchitecture (adapted from: http://www.brsoc.org.uk/gallery). 
The three main pathogenic mechanisms leading to osteoporosis are failure to achieve a strong skeleton 
during growth and development, excessive bone resorption, and failure to replace lost bone due to bone 
formation defects (Raisz 2005). There are numerous causes of these three malfunctions of the bone 
remodeling process. Estrogen deficiency is known to play a critical role in the development of osteoporosis; 
this explains why women are very likely to develop osteoporosis after the abrupt cessation of ovarian 
function during the menopausal transition. Men also show a slight but steady decrease in estradiol and 
testosterone levels with aging, which can manifest itself in osteoporosis (Pietschmann, Rauner et al. 2009). 
Idiopathic, postmenopausal osteoporosis in women and senile osteoporosis affecting both genders are 
grouped as primary osteoporosis. In contrary, bone loss that occurs due to external factors, such as certain 
types of medication (e.g. corticosteroids), and forms due to endocrine diseases is classified as secondary 
osteoporosis (Stromsoe 2004).  
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 Implant Treatment in Low Quality Bone 1.2
Osteoporosis does not only increase fracture risk, but also contributes to the severity of fractures and 
complicates their treatment (Schneider, Goldhahn et al. 2005). The decreased strength of the thinned 
cortical and trabecular bone dramatically affects the primary stability of osteosynthesis implants (Stromsoe, 
Kok et al. 1993; Lim, An et al. 1995). Furthermore, experimental and clinical data suggests that osteoporosis 
negatively influences fracture healing (Kubo, Shiga et al. 1999; Namkung-Matthai, Appleyard et al. 2001; 
Nikolaou, Efstathopoulos et al. 2009) and osteointegration and therefore also the secondary stability of 
implants (Blomqvist, Alberius et al. 1996; Schneider, Goldhahn et al. 2005). Osteosynthesis implants, such 
as typical plate screw constructs or intramedullary nails (Figure 1.4) were initially developed for younger 
patients with healthy, strong bones and they are often not well adapted to the needs of patients with 
fragile osteoporotic bones.  
 
Figure 1.4:   Examples for trauma implants, left: proximal tibia plate, middle: distal radius plate, right: intramedullary nail proximal 
femur (adapted from https://www2.aofoundation.org/wps/portal/surgery). 
1.2.1 Osteoporotic fractures 
Osteoporosis causes more than 8.9 million fractures worldwide per year, this corresponds to around 1000 
fractures per hour (Johnell and Kanis 2006). Loss of mechanical strength due to a decreased thickness and 
increased porosity of the cortical bone can be partially compensated for in the diaphyseal area of long 
bones by an increase in bone diameter as is typically seen in osteoporotic patients. This mechanism does 
not work for the rarefaction of the trabecular network in the metaphyseal regions, the reason why 
osteoporotic bone is more likely to fracture at this sites under heavy mechanical load (Stromsoe 2004). 
Fractures in trabecular regions such as the vertebrae, distal radius and proximal femur (hip) are therefore 
regarded as typical osteoporotic fractures (Hernlund, Svedbom et al. 2013). Large prospective studies have 
shown that the risk for almost all types of fractures are increased in patients suffering from osteoporosis 
(Cummings and Melton 2002). The fracture risk typically increases with age due to age-related decrease in 
bone mineral density combined with an increasing number of falls in older patients (Cummings and Melton 
2002). The age-dependent rapid rise in incidence of vertebral fractures is shown as an example in Figure 
1.5. Osteoporotic fractures are not only painful for the affected patients, but hip fractures especially are 
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also associated with an increased morbidity. In 2010, the number of deaths causally related to osteoporotic 
fractures in the EU was estimated to be 43,000 (Hernlund, Svedbom et al. 2013). 
 
Figure 1.5:   Incidence of vertebral fractures in women and men from Europe by age group (Cummings and Melton 2002). 
1.2.2 Improving Implant Fixation in Low Quality Bone 
The behavior of bone under load can be compared to that of a stiff spring that deforms when loaded and 
regains its original shape once the load is removed. The phenomenon can be distorted when a typically less 
elastic metal implant is attached to the bone. Therefore, implants that rely on the holding power of the 
screws in the bone are more sensitive to the inherent bone material properties than implants that achieve 
structural stability with locking bolts (Stromsoe 2004). The classical osteosynthesis plate gets its stability 
from the friction between the cortical bone surface and the plate, and only works if the screws are well 
anchored in the bone (Figure 1.6 left). As a consequence, the screws create a lot of stress in the 
surrounding bone structure, especially in sites with low bone density since screw holding power is known to 
be linearly correlated to loss of bone mass (Stromsoe, Kok et al. 1993). The result can be a cutout of the 
screws in the bone with resulting implant loosening and instability, a condition that often impairs fracture 
healing. Currently, the most successful strategy to ameliorate implant fixation problems in low quality bone 
is the use of angular stable constructs, for example screws that are locked directly to the plate (Figure 1.6 
right). These angularly stable implants are much less dependent on screw holding power since no friction 
between the plate and the cortical bone is required (Sommer, Gautier et al. 2003; Stromsoe 2004; 
Kammerlander, Erhart et al. 2013).  
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Figure 1.6:   Principle of the angular stable plate (right) in comparison with a classical osteosynthesis plate (left)  
(adapted from https://www2.aofoundation.org/wps/portal/surgery). 
Another strategy to improve implant fixation, especially in trabecular bone, is the use of cement. Cement 
typically consists of polymethylmethacrylate (PMMA) or tricalcium phosphate (TCP). Cements can increase 
the contact area between bone and implant to improve the primary stability of the implant (Lindner, 
Kanakaris et al. 2009; Dall'Oca, Maluta et al. 2010; Kammerlander, Erhart et al. 2013). Despite improved 
fixation, the non-resorbable PMMA and the very slowly resorbable TCP cements are nevertheless 
associated with poor long-term outcome for patients (Lindner, Kanakaris et al. 2009). Even with some 
improvement of the implantation anchorage in low quality bone due to the above mentioned mechanical 
solutions, the complication rates after implantation are still high (Broderick, Bruce-Brand et al. 2013). 
Therefore, new approaches for a fast and sustainable improvement of the bone quality around the implant 
without negative long-term effects are needed. One of the most promising strategies developed during the 
last decade is a local delivery of either anabolic or anti-catabolic drugs to the peri-implant bone (Pioletti, 
Gauthier et al. 2008). The local delivery routine is particularly interesting for drugs with a high affinity to 
bone, such as bisphosphonates, since those substances stay highly localized after administration and 
therefore do not require a special release profile (McKenzie, Dennis Bobyn et al. 2011). 
 Bisphosphonates 1.3
Bisphosphonates (BPs) are today the most important anti-resorptive drugs for the treatment of metabolic 
bone diseases such as osteoporosis, Paget’s disease, hypercalcemia and tumor-associated osteolysis 
(Rogers, Gordon et al. 2000). They were first synthetized in the 1800’s but have been progressively used in 
clinics only in the past 40 years (Russell 2011). This important group of drugs is characterized by a 
chemically stable structure made up of P-C-P bonds similar to that of inorganic pyrophosphates (PPi) that 
act as endogenous “water softeners” in the body (Figure 1.7) (Russell 2011). This P-C-P group makes the 
molecule resistant to chemical and enzymatic hydrolysis, therefore BPs are not metabolized in the body 
and are excreted unaltered (Russell, Watts et al. 2008). At the same time, the double phosphate groups 
chelate with Ca2+ ions and thus cause the high affinity of the molecule to bone mineral. This affinity gives 
BPs the unique property of having a selective uptake by the target organ (Russell, Watts et al. 2008). 
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Researchers have discovered that both the affinity of BPs to bone as well as the potency of BPs can be 
altered by changing the R1 and R2 side chains of the BP molecule (Rogers, Frith et al. 1999; Russell, Watts et 
al. 2008).  
 
Figure 1.7:   Chemical structure of bisphosphonates compared to the naturally occurring pyrophosphate. 
Studies using radiolabeled BPs measured the uptake and retention of different BPs in the bone. The 
resulting data showed that approximately one to two thirds of the administered BP is absorbed into the 
skeleton while the remainder is expelled in the urine within a few hours of administration (Khan, Kanis et 
al. 1997; Thompson, Rogers et al. 2006). Nevertheless, small amounts of BPs can be detected in the urine 
for a long time after administration, this means that BPs are still released from the bone into the blood 
stream and are ready for a re-uptake into the bone (Khan, Kanis et al. 1997; Russell, Watts et al. 2008). This 
finding explains the prolonged periods of pharmacological action of BPs.  
1.3.1 Molecular Mechanisms and Mode of Action of Bisphosphonates 
There are two main groups of BPs, simple BPs and nitrogen-containing BPs, which have significantly 
different modes of action. Etidronate and Clodronate are typical examples of simple BPs, which were the 
first generation of this anti-resorptive group of drugs. Simple BPs are known to be converted into 
methylene-containing analogues of ATP in cells. This substance accumulates to toxic concentrations in the 
cytosol of all cell types which can incorporate BPs, such as osteoclasts and macrophages, leading to 
apoptosis of the affected cells (Roelofs, Thompson et al. 2006).  
Not only is the mode of action of nitrogen-containing BPs (N-BPs) different, but this difference makes them 
several orders of magnitude more potent than simple BPs. N-BPs such as Alendronate and Zoledronate act 
by inhibiting the farnesyl diphosphate synthase in the cell which blocks prenylation of small GTPases. The 
accumulation of unprenylated GTPases in the cytoplasm of the osteoclasts leads to a disruption of the 
normal osteoclast function and apoptosis (Green, Muller et al. 1994; Green and Rogers 2002).  
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Figure 1.8:   Mode of action of bisphosphonates on osteoclasts. 
The acidic pH in the resorption lacuna of the osteoclasts causes a dissociation of the BP from the 
hydroxyapatite (Ebetino, Francis et al. 1998). The dissociated BP can then be taken up by the osteoclast, 
most likely via fluid-phase endocytosis (Thompson, Rogers et al. 2006) (Figure 1.8).  
Besides the known inhibitory effect of BPs on osteoclasts, effects on other bone cells have been described 
as well, but the exact mechanisms are not clear yet (Roelofs, Thompson et al. 2006; Idris, Rojas et al. 2008). 
It has been reported that low concentrations of BPs can protect osteoblasts and osteocytes against 
apoptosis (Plotkin, Weinstein et al. 1999; Plotkin, Manolagas et al. 2006), stimulate the mineralized bone 
nodule formation in vitro (Giuliani, Pedrazzoni et al. 1998), and have a beneficial effect on osteoblast 
differentiation and protein synthesis (Greiner, Kadow-Romacker et al. 2006). Other studies demonstrated 
an improved mineralization and proliferation of human osteoblast-like cells exposed to Zoledronate (Pan, 
To et al. 2004). But also conflicting results can be found showing that especially aminobisphosphonates 
inhibit mineralization and osteoblast growth, induce osteoblast apoptosis and inhibit protein prenylation in 
osteoblasts in vitro in a dose-dependent manner (Idris, Rojas et al. 2008; Orriss, Key et al. 2009). Those 
findings show that in vitro effects of BPs require a careful interpretation as different experimental designs, 
BP types and concentrations can drastically influence the results. In contrary to the in vitro situation, bone 
cells would not be exposed to BP solutions over a long time in the body as the drug is absorbed rapidly to 
the bone mineral surface. Furthermore, the significance of the in vitro results for the in vivo situation is 
unclear as the reduced osteoclast activity can have numerous indirect effects on the bone remodeling cycle 
(Maruotti, Corrado et al. 2012). Published in vivo studies are also not conclusive regarding the influence of 
BPs on other cells than osteoclasts. Depending on the experimental setup used, a positive, negative or no 
influence on bone formation were reported (Tobias, Chow et al. 1993; Brouwers, Lambers et al. 2008; 
Gasser, Ingold et al. 2008; Recker, Delmas et al. 2008; Belfrage, Isaksson et al. 2012).  
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1.3.2 Local Release of Bisphosphonates 
After the big success of systemically administered BPs in clinics, researchers focused also on the local 
delivery of this drug. The local administration routine became of particular interest for cases where existing 
bone needs to be preserved and augmented in specific regions of the body, e.g. around an implant, while 
avoiding side effects related to a systemic administration such as atypical fractures (Pazianas, Cooper et al. 
2010; Watts and Diab 2010). This is an important aspect as many of the today used drugs for osteoporosis 
treatment have been shown to not affect all parts of the skeleton the same way (Hernlund, Svedbom et al. 
2013) and to cause adverse effects (Ott 2005; Watts and Diab 2010; Reginster, Pelousse et al. 2013; Verron 
and Bouler 2014). The delivery of BPs was demonstrated to be very efficient in enhancing bone mass 
locally. Numerous studies showed that a local release of BPs can enhance peri-implant bone density 
(Roshan-Ghias, Arnoldi et al. 2011; Bobyn, Thompson et al. 2014), implant fixation (Astrand and Aspenberg 
2004; Tengvall, Skoglund et al. 2004; Peter, Gauthier et al. 2006; Hilding and Aspenberg 2007) and the 
repair of bony defects (Srisubut, Teerakapong et al. 2007; Cottrell, Vales et al. 2010) in animal models and 
humans. Furthermore it was shown to preserve bone allografts (Åstrand, Harding et al. 2006; Jakobsen, 
Baas et al. 2010) as well as bone sites affected by osteonecrosis (Cheng, Murphy et al. 2013). Despite the 
promising results, there are still no products for a local delivery of bisphosphonates on the market 
available. 
1.3.3 Delivery Systems for Bisphosphonates 
As a local delivery requires a direct access to bone, which is the target site of BPs, it is usually indicated 
during a surgical intervention such as a fracture treatment. In this context, it is a logical approach to link the 
drug directly to commonly used implants or biomaterials. Due to the high affinity of BPs to bone mineral, 
the easiest way to combine BP and implant is a simple absorption of the drug to either a commercially 
available hydroxyapatite coating for metal implants or to mineral containing biomaterials. Both strategies 
have already been shown to be successful. Peter et al. demonstrated that a Zoledronate-loaded 
hydroxyapatite coating could enhance the implant fixation in osteoporotic rats (Peter, Gauthier et al. 2006). 
Others improved bone formation with Alendronate coated bioactive glass (Srisubut, Teerakapong et al. 
2007) or Zoledronate-loaded tricalcium phosphate bone cement (Sörensen, Arnoldi et al. 2013) in rat 
models. But not only ceramic materials were used for the delivery of BPs. Greiner et al. incorporated 
Zoledronate in a polylactide (PLLA) coating and showed an accelerated fracture healing in a rat model 
(Greiner, Wildemann et al. 2008). Abtahi et al. were the first to perform a clinical trial with BP coated 
implants. They implanted dental implants coated with Zoledronate that was immobilized via a fibrinogen 
layer on the metal surface in 16 patients. After 2 and 6 months they were able to show a decreased peri-
implant bone resorption and an increased implant stability (Abtahi, Tengvall et al. 2012). 
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 Evaluation of Implant Outcome 1.4
Whenever new techniques intended to improve implant fixation are introduced, it is important to prove an 
enhanced efficiency compared to existing systems. Implant stability is usually characterized with two terms: 
the primary stability that describes the initial fixation of the implant directly after insertion and the 
secondary stability characterizing the long-term fixation after the remodeling of the peri-implant bone. A 
good primary stability is associated with a stable mechanical engagement between implant and 
surrounding bone, which helps to avoid instabilities and micro-movements. This stable situation is a 
prerequisite for a successful peri-implant bone regeneration resulting in a good secondary stability 
afterwards (Javed, Ahmed et al. 2013).  
The primary stability of implants is usually tested with artificial bone substitutes or cadaveric human or 
animal bones (Steeves, Stone et al. 2005; Poukalova, Yakacki et al. 2010). The evaluation of the secondary 
stability however requires the performance of in vivo studies in suitable animal models or clinical studies in 
humans as the peri-implant bone remodeling cannot be simulated in vitro (Peter, Gauthier et al. 2006; Gao, 
Zou et al. 2009; Abtahi, Tengvall et al. 2012).  
1.4.1 Mechanical Testing of the Implant Stability 
The traditional way of testing the anchorage of implants and especially screws in bone are biomechanical 
tests such as  pullout-, pushout- or torque-tests (Cho and Park 2003; Gao, Luo et al. 2009; Qi, Hu et al. 2012; 
Stadlinger, Korn et al. 2012). Those tests can be used to evaluate both primary and secondary stabilities. 
The test parameters are usually adapted to the type and size of the implant so that it is often difficult to 
compare results. Therefore, ASTM standards were set (e.g. ASTM F543-13E1 “Standard Specification and 
Test Methods for metallic medical Bone Screws”) that should be followed if applicable. The main 
disadvantage of most mechanical tests is their destructive character that does not allow a re-use of the 
samples. There are only a few methods such as the resonance frequency analysis/vibration analysis or the 
cutting torque resistance analysis that allow a non-destructive mechanical testing and can therefore be 
used also in vivo (Atsumi, Park et al. 2007; Degidi, Daprile et al. 2013). As those techniques require a direct 
access to the implant, they are almost exclusively used for dental implants (Abtahi, Tengvall et al. 2010). 
1.4.2 Numerical Evaluation of the Implant Stability 
Due to the destructive character of most mechanical tests (section 1.4.1) the in vivo monitoring of the 
fixation of orthopedic implants was always a challenge. A big step forward was done when the first studies 
show that a simulation of the implant stability can be done by means of micro-finite-element (microFE) 
analysis (Wirth, Mueller et al. 2010; Wirth, Muller et al. 2010). This rather new technique is based on the 
microCT images that can be performed multiple times in vivo due to their non-invasive character. The high-
resolution three-dimensional scans are in a second step transformed into a numerical model with the 
typical bone parameters assigned to its elements (Pistoia, Van Rietbergen et al. 2002). The models can then 
be used to simulate mechanical experiments such as pullout tests (Figure 1.9). Wirth et al. demonstrated 
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excellent correlations between the  pullout strength predicted with microFE and the experimentally 
measured  pullout strength in an ovine vertebra model (Wirth, Mueller et al. 2010). Stadelmann et al. were 
the first that used in vivo microCT data from a rat study for their microFE models and monitored this way 
the time course of the failure load and the bone-screw stiffness of bone screws implanted in rat tibiae 
(Stadelmann, Conway et al. 2013). Using in vivo data has the huge advantage over destructive mechanical 
tests that it allows a close and direct monitoring of the time course of implant stability with a significantly 
reduced number of animals. At the same time the important parameters affecting the implant fixation can 
be identified easily due to the direct link between bone structure (microCT based bone analysis) and 
implant stability (microCT based microFE) (Wirth, Goldhahn et al. 2011).  
 
Figure 1.9:   Principle of the microCT-based microFE analysis: microCT scans (left) are transferred into detailed finite element 
models (right) that can predict the implant fixation in a non-destructive way (images taken from (Wirth, Mueller et al. 2010)). 
1.4.3 Bone Analysis with CT-Based Dynamic Bone Histomorphometry 
When investigating the effect of bone-active drugs, there is a great interest in monitoring the bone changes 
in vivo without having to sacrifice the experimental animals. The only technique that allows today to do so 
over longer time periods is the so-called dynamic histomorphometry, a technique that is based on the 
comparison of time-lapsed CT scans (Waarsing, Day et al. 2004; Schulte, Lambers et al. 2011). The non-
destructive character of the dynamic histomorphometry is a big advantage against the traditional two-
dimensional histology-based histomorphometry as it is for the microFE compared to mechanical testing. 
Another decisive benefit of the microCT-based technique compared to histology is that bone resorption can 
be quantified in a direct manner, this is very useful when studying the effect of anti-resorptive drugs such 
as BPs (Schulte, Lambers et al. 2011). One inherent limitation of this technique is the limited resolution of 
research in vivo microCT scanners that is typically around several µm and around 1 mm for clinical CTs. So 
far the CT-based dynamic histomorphometry was used to study bone changes in mouse vertebrae following 
overiectomy (Lambers, Kuhn et al. 2012) and mechanical stimulation (Schulte, Lambers et al. 2011). Others 
investigated with this technique changes in of the rat tibia in aged and ovariectomized rats (Waarsing, Day 
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et al. 2006) and the bone ingrowth in a scaffold implanted in the femoral condyles of rats (Roshan-Ghias, 
Lambers et al. 2011). 
The CT-based dynamic histomorphometry requires a series of microCT scans taken sequentially from the 
same bone site in the same animal. Then, in a first step, all scans are superimposed with a registration 
algorithm, as it is not possible to perform the CT scans always in an identical position. The second step of 
this technique is a voxel-wise comparison of two consecutive image datasets (Figure 1.10). Bone volume 
that is present only on the first microCT scan is considered as being resorbed, the one present only on the 
second scan is considered as formed. This way it is possible to monitor bone remodeling in 3 dimensions 
over long time periods.  
 
Figure 1.10:   Principle of the µCT based dynamic histomorphometry. 
Static and dynamic bone parameters can then be assessed with the CT-based dynamic histomorphometry. 
Static parameters are measured for a specific time point separately on each of the performed microCT 
scans, their time-dependent changes (dynamic parameters) can be investigated by comparing the values of 
different time points. Examples for static bone parameters are the often-used bone volume fraction 
(BV/TB), trabecular thickness (Tb.Th) or structure model index (SMI). The dynamic bone parameters can be 
the volume based bone formation rate (BFR) or bone resorption rate (BRR) that were measured in this 
study by dividing the formed/resorbed bone by the quiescent bone and by the number of days between the 
two scans. It is important to choose an adequate time interval between two scans (typically several days up 
to 2 weeks for small rodents) which is long enough to be able to see changes but at the same time short 
enough so that clear changes (e.g. bone formation followed by bone resorption at the same site) are not 
missed. 
 Scope of the Thesis 1.5
This thesis was prepared in the framework of a Commission for Technology and Innovation Switzerland 
(CTI)-funded project in collaboration with two industrial partners. Therefore, the industrial background is 
mentioned as this aspect influenced significantly the performed work.  
Introduction 
30 
1.5.1 Industrial Background 
The total costs caused by osteoporosis in the EU in 2010 was estimated at €37 billion – out of which 66% 
were spent for treating incident fractures, 29% for long-term fracture care and only 5% for the 
pharmacological prevention (Hernlund, Svedbom et al. 2013). Especially the €10.7 billion spend for the 
long-term treatment of fractures show that there is still a high demand for new implants that are adapted 
to the special needs of osteoporotic patients and can significantly improve the patient’s outcomes. As 
shown above, effort has been made to improve the existing mechanical solutions and implant designs but 
they have inherent limitations. One very promising approach that came up during the last years and might 
help to overcome those limitations is the use of drug-implant combination products. For this strategy, 
implants that are already well adapted for osteoporotic bone can be combined with local drug delivery 
which can additionally enhance their performance.  
The annual number of osteoporotic fractures in the EU is expected rise from 3.5 million in 2010 to 4.5 
million in 2025, corresponding to an increase of 28% (Hernlund, Svedbom et al. 2013). Those numbers 
cause a significant growth in all trauma device segments with a continuing shift towards premium price 
devices. Surgeons that are facing more and more patients with insufficient bone quality demand new 
solutions and are motivated to adopt new technologies. Manufactured in Switzerland, a BP releasing drug 
delivery system with a high clinical performance is expected to have a great market potential in Europe, the 
US and Japan. 
1.5.2 Objectives of the Thesis 
The overall goal of this thesis is the development of a Zoledronate delivery system that can locally enhance 
peri-implant bone quality and as a result implant fixation. An overview about the specific aims is shown in 
Figure 1.11. 
 
Figure 1.11:   Overall objective and specific aims of this thesis. 
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1.5.3 Aim 1: Investigation of the Zoledronate Effect on Peri-Implant Bone 
Based on a literature survey, it is clear that many research projects have already tested and evaluated the 
local delivery of BPs to peri-implant bone. Most of those studies revealed an improved bone density and 
bone-implant contact after several weeks. However, as those results were mostly gained with terminal 
measurements like histology or ex vivo microCT scans, so there is no information available about the exact 
drug range and mode of action that leads to the increased bone density. We are therefore the first ones 
using the microCT based dynamic histomorphometry to study the peri-implant bone remodeling and how it 
is altered by the presence of locally delivered Zoledronate in an ovariectomized rat model of 
postmenopausal osteoporosis. The study design and results of aim 1 can be found in chapter 2. 
1.5.4 Aim 2: Development of a Drug Delivery System 
The second aim of this thesis is the development of a suitable drug delivery system based on the 
information gained from aim 1. We started with a Zoledronate-loaded polylactide (PDLLA) coating that was 
directly applied to the surface of the implant. However, due to insoluble problems with the mechanical 
abrasion resistance and difficulties with a precise drug dosing, we had to switch concepts and started 
working on a stand-alone system that is applied to the prepared implant bed before implant insertion. After 
working on different scaffold solutions, we tried for the first time the use of a Zoledronate-loaded hydrogel 
that came out to be very suitable during the in vivo studies for aim 1. We then evaluated other 
functionalities to the hydrogel like the possibility to improve the primary stability of the implant by adding 
different materials. The development process of the drug delivery system and the results are described in 
chapter 3 and in the annex. 
1.5.5 Aim 3: Evaluation of the Implant Fixation with µFinite-Element-Analysis 
The third and last goal of this thesis is the evaluation of the implant stability induced by the developed drug 
delivery system. We were able to demonstrate in vivo in a rat model that locally delivered Zoledronate can 
significantly enhance the bone density around implants. The proof that a higher peri-implant bone density 
is resulting in a better implant fixation was still missing. A numerical simulation of the pullout test was 
performed based on the microCT datasets that were acquired for the dynamic histomorphometry. This 
technique has been shown in literature to correlate well with the actual implant fixation (Wirth, Goldhahn 
et al. 2011; Wirth, Müller et al. 2012; Stadelmann, Conway et al. 2013). Furthermore, it offers the 
possibility to evaluate the evolution of the implant fixation over time, which is not possible with a 
destructive, experimental pullout test. 
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 Abstract  2.1
Bisphosphonates are known for their strong inhibitory effect on bone resorption. Their influence on bone 
formation however is less clear. In this study we investigated the spatio-temporal effect of locally delivered 
Zoledronate on peri-implant bone formation and resorption in an ovariectomized rat femoral model. A 
cross-linked hyaluronic acid hydrogel was loaded with the drug and applied bilaterally in predrilled holes 
before inserting polymer screws. Static and dynamic bone parameters were analyzed based on in vivo 
microCT scans performed first weekly and then biweekly. The results showed that the locally released 
Zoledronate boosted bone formation rate up to 100% during the first 17 days after implantation and 
reduced the bone resorption rate up to 1000% later on. This shift in bone remodeling resulted in an 
increase in bone volume fraction (BV/TV) by 300% close to the screw and 100% further away. The double 
effect on bone formation and resorption indicates a great potential of Zoledronate-loaded hydrogel for 
enhancement of peri-implant bone volume which is directly linked to improved implant fixation. 
Keywords: Drug delivery; hydrogel; bisphosphonate; implant; dynamic histomorphometry; microCT 
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 Introduction 2.2
The human skeleton is constantly renewed and repaired by the bone remodeling process, a well-
coordinated sequence of osteoclast-mediated bone resorption and osteoblast-mediated bone formation 
(Seeman 2009; Boyce, Rosenberg et al. 2012). Anti-catabolic drugs, such as bisphosphonates (BPs), can slow 
down this process and shift the balance between bone formation and resorption activity by selectively 
affecting osteoclast function (Riggs and Parfitt 2005). Osteoclasts are considered to be the main target for 
BPs as only this cell type can liberate and internalize mineral bound BPs during the resorption process 
(Rogers, Gordon et al. 2000; Russell, Watts et al. 2008). However, effects of BPs on cells of the osteoblast 
lineage have also been described, which raises the question if BPs can also enhance bone formation activity 
(Roelofs, Thompson et al. 2006; Idris, Rojas et al. 2008). In vitro experiments have shown that low 
concentrations of BPs can protect osteoblasts and osteocytes against apoptosis (Plotkin, Weinstein et al. 
1999; Plotkin, Manolagas et al. 2006), stimulate mineralized bone nodule formation (Giuliani, Pedrazzoni et 
al. 1998), and have a beneficial effect on osteoblast differentiation and protein synthesis (Greiner, Kadow-
Romacker et al. 2006). Specifically for Zoledronate, the most potent bisphosphonate used in clinics today, 
an improved mineralization and proliferation of human osteoblast-like cells has been demonstrated (Pan, 
To et al. 2004). However, conflicting results can also be found showing that BPs might inhibit mineralization 
and osteoblast growth, induce osteoblast apoptosis, and inhibit protein prenylation in osteoblasts in a 
dose-dependent manner (Idris, Rojas et al. 2008; Orriss, Key et al. 2009). Taken together, these findings 
suggest that BPs might, in addition to their known anti-resorptive effect, also have the ability to stimulate 
bone formation. 
BPs are usually administered orally or intravenously. Local application is of particular interest in cases 
where existing bone needs to be preserved and augmented whilst avoiding the known side effects related 
to systemic administration (Pazianas, Cooper et al. 2010; Watts and Diab 2010). Several in vivo studies have 
shown that a local delivery of BPs can enhance peri-implant bone density (Roshan-Ghias, Arnoldi et al. 
2011; Bobyn, Thompson et al. 2014), implant fixation (Astrand and Aspenberg 2004; Tengvall, Skoglund et 
al. 2004; Peter, Gauthier et al. 2006; Hilding and Aspenberg 2007; Andersson, Agholme et al. 2010), and the 
repair of bony defects (Srisubut, Teerakapong et al. 2007; Cottrell, Vales et al. 2010) in animal models and 
humans. Furthermore BPs have been shown to preserve bone allografts (Åstrand, Harding et al. 2006; 
Jakobsen, Baas et al. 2010) as well as bone sites affected by osteonecrosis (Cheng, Murphy et al. 2013).  
Currently published studies are mostly based on static analysis techniques like single CT/microCT scans, 
histology or  pullout/pushout tests performed after euthanasia of the animals (Peter, Gauthier et al. 2006; 
Andersson, Agholme et al. 2010; Back, Pauly et al. 2012). These techniques do not allow a separate 
investigation of the dynamic bone formation and bone resorption processes. Few studies can be found that 
looked at dynamic bone parameters after a systemic administration of BPs, but they did not show 
enhanced bone formation activity in humans nor in animals (Gasser, Ingold et al. 2008; Recker, Delmas et 
al. 2008). Some studies even demonstrated reduced bone formation and a suppressed activity of pre-
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existing bone-forming surfaces at medium to high doses of BPs (Tobias, Chow et al. 1993; Allen, Follet et al. 
2006; Brouwers, Lambers et al. 2008; Fuchs, Phipps et al. 2008; Belfrage, Isaksson et al. 2012).  
Therefore, the aim of the present study is to investigate the spatio-temporal effect of locally delivered 
Zoledronate on peri-implant bone remodeling using the so-called dynamic histomorphometry. This 
previously developed microCT-based technique enables us to quantitatively measure the average outcome 
of bone formation and resorption over long time periods (Waarsing, Day et al. 2004; Schulte, Lambers et al. 
2011), allowing an investigation of the so far unclear effect of locally applied BPs on the dynamic bone 
formation processes. Understanding the effects of Zoledronate and how it interacts with normal bone 
healing is important when it comes to designing drug delivering implants and materials. The active range, 
the time delay, and duration of the BPs’ effects (very local versus widespread, fast versus slow, long term 
versus short term effects) are crucial for targeting specific bone sites, as well as certain phases of bone 
healing. 
 Materials and Methods 2.3
2.3.1 General Study Design 
Custom-made polymeric miniature screws were implanted bilaterally in the femoral condyles of 
ovariectomized (OVX) rats. Unlike metal implants, these screws are visible on microCT scans without 
creating image disturbing artifacts. A hydrogel based drug delivery system was used to release Zoledronate 
into the peri-implant bone stock. During surgery, the hydrogel was inserted into the predrilled screw-hole 
before screw implantation. The study included 3 experimental groups with 4 animals assigned to each 
group. In the first group, the hydrogel was loaded with 5 µg Zoledronate (Zol-Gel-group); in the second 
group, unloaded hydrogel was used (Gel-group); and in the third group, no hydrogel was inserted (Control-
group) before screw implantation. Time-lapsed in vivo microCT scans of the animals were performed for 
close monitoring of the bone response to the implantation and how it is altered by the bisphosphonates 
delivery. A time line of the study is shown in Figure 2.1. 
 
Figure 2.1:   Timeline of the study; the rats are ovariectomized at an age of 17 weeks followed by the bilateral implantation of 
miniature screws at an age of 22 weeks. Two microCT scans were performed to confirm the bone loss after OVX, 6 more were 
performed after the screw implantation to monitor bone remodeling. 
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2.3.2 Hydrogel Preparation 
A commercially available cross-linked hyaluronic acid (Termira AuxiGel™, Stockholm, Sweden) was used as 
the drug delivery system for the BPs because this gel had already been shown to be a suitable material for 
delivering drugs such as growth factors to bone (Bergman, Engstrand et al. 2009; Martínez-Sanz, Varghese 
et al. 2012; Kisiel, Klar et al. 2013; Martínez-Álvarez, González-Meli et al. 2013). The crosslinking of the 
hydrogel is achieved by mixing a hyaluronan derivative (component A) with a PVA cross-linker (component 
B). First, an aqueous solution containing 2 mg/ml Zoledronate (Art.-Nr. ALX-430-153-0000, Enzo Life 
Sciences, Farmingdale, USA) was prepared. The exact drug dose was ensured by mixing precisely weighed 
and measured amounts of Zoledronate and distilled water. All solutions were sterile filtered and the mixing 
of the gels was performed under sterile conditions. Five parts of the Zoledronate solution were mixed with 
3 parts of component A and 2 parts of component B for the Zol-Gel-group. The Zoledronate solution was 
replaced by bi-distilled water for the Gel-group. The resulting gels were allowed to settle for 1 h before 
filling the capillary pistons of a positive displacement pipette (Microman®, Gilson, Middleton, USA) with 5 μl 
gel each. The capillaries were pulled off the pipette with the gel inside and left 1 h for settling. Then they 
were sterile packed in plastic tubes and frozen at -20°C.  
2.3.3 Animal Model 
All animal procedures were approved by the local animal care and use committee (license no. 2508.1, 
EXPANIM, SCAV, Epalinges, Switzerland). Twelve 14 week old virgin female rats were received from Janvier 
Labs (Saint-Berthevin, France) and acclimatized in the animal facilities for 3 weeks. All rats were housed 4 
per cage under 12 h light to 12 h dark cycles at 22°C room temperature with 55% humidity. They were fed 
with a standard rodent diet (KLIBA NAFAG 3436, Provimi Kliba AG, Switzerland) and tap water at libitum. 
After ovariectomy (OVX), food intake was limited to 50 g per kg body weight per day. Sterilized hay, paper 
tunnels and wooden sticks were offered as cage environment enrichment. The animals were fed in groups 
and equal nutrition of all animals was ensured by close monitoring and regular weighing.  
2.3.4 Surgical Procedures 
Ovariectomy 
The rats were ovariectomized bilaterally at an age of 17 weeks and a weight of 293 ± 11 g to induce an 
estrogen deficiency related bone loss (Hogan, Ruhmann et al. 2000). We used a dorsal approach similar to 
the procedure described by Alghamdi et al (Alghamdi, Bosco et al. 2013). Buprenorphine (Temgesic®, 
Reckitt Benckiser AG, Wallisellen, Switzerland) was administered subcutaneously before surgery and every 
8 h for the first 48 h after surgery for pain relief. Paracetamol (Dafalgan 500 mg effervescent tablet, UPSA 
Bristol-Myers Squibb SA, Baar, Switzerland) was added to the drinking water of the rats for 5 days. The skin 
incisions were closed with running subcuticular sutures (Vinyl 5.0, Ethicon, Somerville NJ, USA) so that the 
rats did not have to be kept in separate cages after the surgery. No antibiotics were given. 
Investigation of the Effect of Locally Delivered Zoledronate on Peri-Implant Bone 
42 
Screw Implantation 
Screws were implanted when the rats were aged 22 weeks and weighed 338 ± 18 g. One miniature screw 
was implanted in each femoral condyle under Isoflurane anesthesia with Buprenorphine to avoid 
intraoperative pain. The surgery was done under aseptic conditions. The rat was prepared for surgery and 
the first leg was fixed on a special table with the knee in a flexed position. A skin incision of 1-2 cm was 
made on the lateral side of the distal femoral end and the muscles were blunt dissected in order to expose 
the condyle. One hole with a diameter of 1.2 mm and 3.5 mm length was drilled unicortically in the condyle 
with a motorized dentist’s drill (DEC 100, Nobelcare, Sweden). The cortex was pre-tapped to avoid 
deformation and damage to the polymer screws. The drilled hole was rinsed with saline solution and 
surgical vacuum was used to remove bone particles. As a next step, the hydrogel was inserted in the 
predrilled hole with a positive displacement pipette before implanting a miniature screw (Figure 2.2). The 
screws with a thread length of 3 mm and a diameter of 1.4 mm were custom made from radiopaque 
polyetheretherketone (RISystem, Davos, Switzerland) with a 100 nm titanium coating to mimic the 
interface with a standard orthopedic screw. After implanting the screw, the fascia of the muscle was closed 
with resorbable sutures (Vinyl 5.0). The skin was closed with interrupted subcuticular sutures (Vicryl 5.0) 
before performing the same procedure at the contralateral femur. The rat was placed in a heated incubator 
for post-surgical recovery. The post-OP medication and care was similar to the procedure after ovariectomy 
described above. 
 
Figure 2.2:   Hydrogel insertion in the predrilled bone hole located in the femoral condyle of the rat; the gel is inserted in the hole 
via a positive displacement pipette before implanting the screw. 
2.3.5 MicroCT Imaging, Data Processing and Analysis 
In vivo MicroCT Imaging 
In vivo microCT scans (Skyscan 1076, Bruker microCT, Kontich, Belgium) of only the right femur were 
performed one day before OVX and one day before screw implantation in order to confirm the bone loss 
caused by the estrogen deficiency. Both femurs were then scanned at day 3, 10, 17, 31, 45, and 58 after 
Investigation of the Effect of Locally Delivered Zoledronate on Peri-Implant Bone 
43 
screw implantation for the dynamic histomorphometry. According to literature, no bone damage due to 
radiation can be expected after 8 consecutive microCT scans (Brouwers, Van Rietbergen et al. 2007). The 
animals were kept under Isoflurane anesthesia during the scans to avoid motion artifacts. The rats were 
euthanized at the time of the last microCT scan with an intraperitoneal injection of Pentobarbital 
(Esconarkon, Streuli Pharma SA, Uznach) while under anesthesia.  
Data Acquisition and Reconstruction 
The parameters for the scans assessing the bone loss before screw implantation were the following: 0.5 
mm aluminum filter, voltage 60 kV, current 167 µA, exposure time 480 ms, rotation step 0.4°. The peri-
implant bone after screw insertion was scanned with different parameters adapted to the density of the 
screw: 0.5 mm aluminum filter, voltage 80 kV, current 120 µA, exposure time 400 ms, rotation step 0.5°. 
The spatial resolution of all scans was 18.4 µm. Two polymer-hydroxyapatite phantoms with known mineral 
density were scanned under the same conditions as the rats and served for a calibration of the bone 
mineral density (BMD) and tissue mineral density (TMD) measurement histograms. The reconstruction of 
the projection images was done with NRecon and GPURecon Server (Bruker microCT, Kontich, Belgium). A 
ring artifact correction of 4 and a beam hardening correction of 20% for the scans assessing bone loss and 
30% for the peri-implant bone scans were set to improve the image quality. The reconstruction output was 
stacks of cross-sections in 8-bit bitmap format. 
Assessment of the Estrogen Deficiency Introduced Bone Loss 
The scans taken before OVX and before screw implantation were analyzed with the software CTan (Bruker 
microCT) to confirm the induced bone loss. A volume of interest (VOI) with a length of 4 mm was defined 
proximal to the growth plate located in the femoral condyle. Cortical and trabecular regions were selected 
automatically with a customized algorithm before analyzing the morphometric parameters as well as the 
BMD of the trabecular region and the TMD of the cortical region.  
MicroCT-based Dynamic Histomorphometry 
The microCT datasets were used to perform dynamic histomorphometry, a technique that is based on the 
registration and comparison of two consecutive microCT scans (Waarsing, Day et al. 2004; Schulte, Lambers 
et al. 2011). Bone was considered to be resorbed if it was present on the first microCT scan and not on the 
second, whereas bone was considered to be formed if it was present on the second scan and did not 
appear on the first. Bone which appeared in both scans was considered to be quiescent. In this way, bone 
remodeling can be monitored in three dimensions over long periods of time without the need to euthanize 
the animals.  
Image processing for the dynamic histomorphometry was done with Amira® (FEI Visualization Sciences 
Group, Burlington, USA) and CTan. In the femoral condyle, a VOI of 4.5 mm in height around the screw was 
manually defined with CTan for all animals. Using an automated algorithm, the background and the patella 
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were removed and the dataset size was reduced to facilitate image processing. Then all datasets were 
loaded into Amira® for further processing with a custom script. The script first super positioned all original 
grey value images using the built-in registration function and their correlations as a similarity measure. 
Each dataset was registered with the image from the previous time step. All images were transformed into 
the coordinate system of the first image using the built-in standard interpolation method and the datasets 
were filtered with a median-based 3D noise-reduction filter. Next, a VOI containing only trabecular bone 
was automatically defined on the first dataset and adapted manually so that it would also fit consecutive 
scans which are slightly different due to ongoing bone remodeling. Then, for all datasets, the VOI was 
binarized with a threshold of 80. By comparing consecutive scans voxel by voxel, resorbed, formed, and 
quiescent bone regions were identified and assigned one of three grey values. Two additional grey values 
were assigned to the screw and the bone marrow. These images were saved and loaded into CTan. The 
static and dynamic bone parameters around the screw were measured in four layers of 368 µm (20 voxels) 
(Figure 2.3). The static bone parameters bone volume fraction (BV/TV), trabecular thickness (Tb.Th), 
trabecular number (Tb.N), trabecular separation (Tb.Sp), and structure model index (SMI) were analyzed for 
a complete assessment of the bone structure changes. The volume-based bone formation rate (BFR) and 
bone resorption rate (BRR) were chosen as representative parameters as their calculation is robust and not 
as sensitive to registration inaccuracies as the surface-based parameters. The bone formation rate is given 
in percent per day (%/d) and calculated as the ratio of formed bone volume to quiescent bone volume 
divided by the number of days between the two scans. The bone resorption rate is calculated as the ratio of 
resorbed bone volume to quiescent bone volume divided by the days between the scans. 
 
Figure 2.3:   Main steps of the dynamic histomorphometry. First, pairs of microCT scans from consecutive time points are registered 
and segmented. The cortex is removed with an automated algorithm and the time points are compared voxel by voxel by assigning 
different grey values to bone present only on the first, only on the second or on both datasets. In a last step, 4 layered VOIs of 368 
µm each are created and analyzed separately for static and dynamic bone parameters. 
2.3.6 Histology 
The rat femurs were dissected just after euthanasia and fixed in 4% paraformaldehyde solution before 
dehydrating them in a series of ethanol solutions with ascending concentration (70%, 80%, 90%, 95% and 
100%). After clearing the samples in toluol, they were embedded by infiltration with methylmethacrylate 
99% (MMA), Bis(tert-butylcyclohexyl) peroxydicarbonate (Perkadox 16) and dibutylphtalate (DBP). All 
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agents were purchased from Sigma-Aldrich (St. Louis, US). After polymerization during 3 weeks at room 
temperature, the samples were cut with a diamond-coated inner diameter saw (Leica SP 1600, Leica 
Microsystems, Wetzlar, Germany) to slices of around 200 µm thickness. Those slices were glued with acrylic 
glue (Loctite 401, Henkel, Düsseldorf, Germany) to custom-made opaque PMMA microscope slides 
(Semadeni, Ostermundingen, Switzerland) and ground to around 60 µm thickness with a grinding machine 
(Pedemax-2, Struers, Willich, Germany). Finally, the surface of the slides was etched with 0.7 % formic acid 
(Applichem, Gatersleben, Germany) before staining it with toluidine blue (VWR, Dietikon, Switzerland). 
Images were taken with an upright light microscope (DM 5500, Leica Microsystems, Wetzlar, Germany). 
2.3.7 Statistics 
Statistical testing was done with Matlab (Mathworks, Natick MA, USA). Values lying outside an interval of 
1.5 times the quartile range were identified as outliers and excluded. The results of the OVX scans were 
analyzed with a paired t-test after performing a Lilliefors test for a normal distribution. In case the normal 
distribution could not be confirmed, a Wilcoxon singed rank test was used. The static and dynamic bone 
parameters were tested for significance with a non-parametric Kruskal Wallis ANOVA followed by a Tukey's 
HSD (Honestly Significant Difference) test since not all groups followed a normal distribution and nor did 
they all have equal variance. 
 Results 2.4
2.4.1 Clinical Observations 
All rats tolerated both surgeries well and returned to normal activity post-surgery. One rat from the Zol-
Gel-group had to be euthanized 4 weeks after screw implantation due to a cholangiocarcinoma that was 
unrelated to the study. The results from this animal were still included in the analysis as the statistical tests 
did not identify them as outliers when compared with the other animals of the same group. The limited 
food intake allowed a controlled weight gain in the animals; their final mean weight was 372 ± 21 g. 
2.4.2 Assessment of the Estrogen Deficiency Induced Bone Loss 
The in vivo microCT scans confirmed that the rats had a diminished BMD, enlarged marrow cavities, and a 
significantly lower trabecular bone volume only 35 days after OVX (Table 2.1). This was shown by the 
decreasing BV/TV and Tb.N, and the increasing Tb.Sp. No significant changes could be detected for the 
Tb.Th. The rising SMI showed that the trabecular bone had shifted from a mainly plate-like structure to a 
more rod-like structure that is typical of osteoporotic bone (Hildebrand and Rüegsegger 1997). However, 
the estrogen deficiency had no short-term influence on the cortical bone. No changes could be detected in 
the cortical thickness (C.Th); the TMD of the cortex increased slightly by 2%.  
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Cancellous Bone Parameters Cortical Bone Parameters 
 BMD 
[g/mm3] 
BV/TV  
[%] 
SMI  
[] 
Tb.Th  
[mm] 
Tb.Sp  
[mm] 
Tb.N  
[1/mm] 
TMD 
[g/mm3] 
C.Th  
[mm] 
before OVX 0.32 ± 0.03 33.4 ± 3.9 1.19 ± 0.25 0.14 ± 0.01 0.32 ± 0.09 2.39 ± 0.32 1.09 ± 0.03 0.55 ± 0.01 
35 d after OVX 0.23 ± 0.04 20.8 ± 4.9 1.79 ± 0.27 0.15 ± 0.02 0.92 ± 0.25 1.39 ± 0.31 1.11 ± 0.03 0.56 ± 0.02 
mean change -28% -38% 50% 7% 191% -42% 2% 0% 
p-value 0.000 0.000 0.001 0.126 0.000 0.000 0.008 0.133 
Table 2.1:   Changes in bone parameters following OVX. Bone within the first 4 mm proximal to the femoral growth plate was 
analyzed. The mean changes were calculated as ratio of the difference between the mean values before and after OVX to the mean 
value before OVX. 
2.4.3 MicroCT-based Dynamic Histomorphometry 
A total of 138 microCT scans were analyzed for the dynamic histomorphometry, of which 2 had to be 
excluded due to motion artifacts. The sample size of the analyzed groups varied from 5 to 8 after removal 
of the outliers. The hyaluronic acid hydrogel used as a drug delivery system did not show any effect on the 
analyzed bone parameters. No significant differences were found between the Control-group and the Gel-
group at any time. Volume rendered comparisons of two time points for one femur from the Gel-group and 
one from the Zol-Gel-group are shown in Figure 2.4. 
 
Figure 2.4:   Three-dimensional visualization of the peri-implant bone indicating bone formation and resorption sites of two 
samples, one from the Gel-group (top), one from the Zol-Gel-group (botton). The data were acquired by a comparison of pairs of 
consecutive microCT scans as described in section 2.5.4. The analyzed trabecular region of the bone is shown in light grey, red and 
green, the screw in dark grey and the cortex in transparent. 
Static Bone Parameters 
Two main bone regions can be distinguished in the results: the inner layer (0-368 µm from screw surface) 
and part of the second layer (368-736 µm) reflect the bone reaction to the screw implantation. The two 
outer layers (736-1472 µm) are not affected by the implant and show stable bone parameters.  
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All experimental groups showed a clear gain in BV/TV, Tb.Th, and Tb.N in direct proximity to the screw 
between day 3 and day 10 after screw implantation (Figure 2.5, 2.6, 2.7). The Tb.Sp and the SMI decreased 
in accordance with the other bone parameters, which indicates a more compact bone structure (Figure 2.8, 
2.9). This gain in bone mass continued for the Zol-Gel-group until day 17 and plateaued at a BV/TV of 
around 55% until the end of the study. In the Control- and the Gel-groups, the initial bone gain was 
followed first by a rapid and then later by a moderate bone loss. The final BV/TV in those two groups was 
around 13%. The effect of Zoledronate diminished with increasing distance from the screw surface. The 
trabecular parameters of the Zol-Gel-group show that the gain in bone volume further from the screw is 
mainly caused by an increasing Tb.N and a decreasing Tb.Sp (Figure 2.6, 2.7). The Tb.Th in the outer two 
layers was identical for all groups and constant throughout the whole study (Figure 2.8).  
  
 
Figure 2.5:   Bone volume/ tissue volume measured in 4 layers around the screw, the grey asterisks indicate the significant 
differences between Zol-Gel-group and Gel-group, the black ones between Control-group and Zol-Gel-group. 
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Figure 2.6:   Trabecular separation measured in 4 layers around the screw, the grey asterisks indicate the significant differences 
between Zol-Gel-group and Gel-group, the black ones between Control-group and Zol-Gel-group. 
 
Figure 2.7:   Trabecular number measured in 4 layers around the screw, the grey asterisks indicate the significant differences 
between Zol-Gel-group and Gel-group, the black ones between Control-group and Zol-Gel-group. 
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Figure 2.8:   Trabecular thickness measured in 4 layers around the screw, the grey asterisks indicate the significant differences 
between Zol-Gel-group and Gel-group, the black ones between Control-group and Zol-Gel-group. 
 
Figure 2.9:   Structure model index measured in 4 layers around the screw, the grey asterisks indicate the significant differences 
between Zol-Gel-group and Gel-group, the black ones between Control-group and Zol-Gel-group. 
Investigation of the Effect of Locally Delivered Zoledronate on Peri-Implant Bone 
50 
Dynamic Bone Parameters 
In direct proximity to the screw, a constant low BRR of around 2-3 %/d was seen for the Zol-Gel-group 
throughout the whole study (Figure 2.10). The Control- and Gel-groups initially showed (day 3-10) an 
equally low BRR followed by a high peak of around 12 %/d from day 10-17. From then onward, the BRR 
diminished until the study end point and reached a value equal to the Zol-Gel-group for the last period 
analyzed, which was 45-58 days after screw implantation. In the outer three layers, the BRR in the Control- 
and Gel-groups was initially very high (8-10 %/day) compared to the Zol-Gel-group (3-5 %/day). This 
difference evened out over time and was no longer significant from day 31-58. 
Unlike the effect of Zoledronate on bone resorption, its influence on bone formation was small. The results 
of the BFR showed that the implantation of the screw induced an early peak in bone formation in the inner 
two layers in all groups (Figure 2.11). The BFR in the Control- and Gel-groups was characterized by a peak of 
around 20 %/d from day 3 to 10, followed by an almost constant low BFR of 1-2 %/d during the rest of the 
study. This phenomenon was also found to a lesser degree in the second layer from 368 – 736 µm where 
the initial BFR reached 10 %/d and then decreased to 2-3 %/d. The BFR in the two outer layers was 
unaffected by the screw implantation and showed a constant value of 3-4 %/d. The initial peak was 
enhanced for the Zol-Gel-group compared to the two other groups, a significant difference was found from 
days 10-17 in the inner layer and from days 3-17 in the second layer. The outer two layers of the Control- 
and the Gel-groups were not affected by the screw implantation and showed a constant BFR of around 5 
%/d. The Zol-Gel-group differed in this region only from day 3-10, where it showed a small but significant 
bone formation peak of 9 %/d in the region from 736-1104 µm respective 6 %/d from 1104-1472 µm.  
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Figure 2.10:   Bone resorption rate measured in 4 layers around the screw, the grey asterisks indicate the significant differences 
between Zol-Gel-group and Gel-group, the black ones between Control-group and Zol-Gel-group. 
 
Figure 2.11:   Bone formation rate measured in 4 layers around the screw, the grey asterisks indicate the significant differences 
between Zol-Gel-group and Gel-group, the black ones between Control-group and Zol-Gel-group. 
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2.4.4 Histology 
Histology results showed that the hyaluronic acid hydrogel was fully degraded after 58 days of implantation 
since hydrogel residues could no longer be detected in neither the Gel- nor the Zol-Gel-groups (Figure 
2.12). The screws were well osteointegrated in all groups; no significant amounts of fibrotic tissue could be 
detected close to the screw surfaces. In the Control- and the Gel-groups, new bone matrix was deposited 
only in direct proximity to the screws; no new bone formation could be detected further away.  
 
Figure 2.12:   Toluidine blue stained ground sections from the Control-group (left), the Gel-group (middle) and the Zol-Gel-group 
(right). The white asterisks in the darker blue regions indicate immature, non-remodeled bone with an irregular structure and large 
amounts of cells, the white arrows on brighter blue regions show mature trabecular bone with less cells and a regular structure. 
Only small periosteal callus formation was visible around the screw heads of the Control- and Gel-groups, 
the bone structure within those calli was still immature. In contrast, a large amount of newly formed bone 
trabeculae were detected close to and further away from the screw surface in the Zol-Gel-group. This 
newly formed bone also showed a woven structure typical of immature bone with an irregular 
arrangement of the collagen fibers, a large cell number and reduced mineral content. In the Zol-Gel-group, 
significant periosteal callus formation was found even far from the implantation site. Normal-shaped 
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osteoclasts and foreign body giant cells were present in all three groups, but to a much lower extent in the 
Zol-Gel-group than in the other two groups. The bone lining osteoblasts seemed to be more activated in 
the Zol-Gel-group compared to Control- and Gel-groups. The histology showed a significantly enhanced 
peri-implant bone density in the Zol-Gel-group. The newly formed bone was not fully remodeled in all 
groups, whereas the bone remodeling in the Zol-Gel-group seemed to be less advanced than in the other 
two groups.  
 Discussion 2.5
The main goal of the present study is to investigate the spatio-temporal effect of locally delivered 
Zoledronate on peri-implant bone remodeling based on time-lapsed microCT scans. In this context, a cross-
linked hyaluronic acid hydrogel was used as drug delivery material. 
The significant new result of this study is an up to 100% increase of the early bone formation rate caused by 
locally delivered Zoledronate that accompanies an efficient inhibition of peri-implant bone resorption. In 
this way, Zoledronate initially boosts bone formation and later on helps to preserve the newly formed 
bone. It is the first in vivo study unambiguously demonstrating the positive effect of Zoledronate on bone 
formation. This result opens new possibilities for local delivery of this drug as well as for the understanding 
of its global effect on bone remodeling.  
MicroCT-based histomorphometry was chosen for this study as it has been shown to be a very suitable 
technique for the quantitative analysis of three-dimensional bone formation and bone resorption rates 
over long in vivo time periods (Schulte, Lambers et al. 2011). Obtaining data from multiple time points 
without having to euthanize the animals is a key advantage of a longitudinal study compared to the 
traditional two-dimensional histology-based histomorphometry. The second benefit of the microCT-based 
technique compared to histology is that bone resorption rate can be quantified in a direct manner that is 
very useful when studying the effect of anti-resorptive drugs such as BPs (Schulte, Lambers et al. 2011). 
Metal induced artifact issues that are typically related to CT scans and complicate the analysis of peri-
implant bone were overcome in the present study by using radiopaque PEEK screws. 
In order to understand the influence of the BPs on the peri-implant bone remodeling, it is important to 
have a look at the normal bone healing as it was found in the Control-group. First, the changes in bone 
structure caused by the estrogen deficiency are consistent with those reported in the literature and 
confirm the success of the OVX (Brouwers, Lambers et al. 2008). The results from the histomorphometry 
performed after screw implantation showed that the bone reaction to the trauma caused by the screw 
implantation took place principally in the two innermost layers (the “bone-healing-zone”, 0-736 µm from 
the screw surface). This zone was characterized by a large increase in bone formation rate during the first 
17 days after the surgery up to a distance of 736 µm from the screw surface. This early peri-implant bone 
formation is in accordance with literature where it was shown to be the result of the so-called static 
osteogenesis (Ferretti, Palumbo et al. 2002; Marco, Milena et al. 2005). Osteogenic cells and a new calcified 
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matrix are therefore deposited after only a few days on the cement line created on the implant surface 
(Meyer, Joos et al. 2004). This rapid deposition of calcified matrix restores the continuity of the bone 
structure, even if the mechanical competence of the woven bone is lower than that of mature remodeled 
bone due to the random orientation of the collagen fibers (Probst and Spiegel 1997). No microCT-based 
studies could be found confirming bone formation this early next to an implant.  
The woven structure of the newly formed bone in the Control-group was confirmed in the present study by 
a decrease in SMI and an increase in Tb.N and Tb.Th that accompanied the gain in BV/TV in the bone-
healing-zone from day 3-10. Woven bone is reported to be progressively remodeled and substituted by 
mature bone with a trabecular structure and delimiting marrow spaces later on (Franchi, Orsini et al. 2004), 
a process that also removes bone debris and necrotized bone caused by the implant bed preparation 
(Futami, Fujii et al. 2000). In the present study, the remodeling was initiated by a significant loss in bone 
volume in the bone-healing-zone that started 10 days after screw implantation in the Control-group.  
Another interesting finding from the Control-group is the initially high, and then progressively decreasing, 
BRR in the outer two layers that are not in contact with the screw (the “bone-remodeling-zone”). This 
phenomenon can be explained by the initial rapid bone loss phase induced by the estrogen deficiency of 
the animals that terminates 3-4 months after OVX (Hogan, Ruhmann et al. 2000). The bone loss is even 
enhanced in this study by the growth of the animals that results in a “flow” of the screw and the 
surrounding volume of interest towards the less trabecularized diaphyseal region. Normally, the growth of 
rats slows down and ceases around 26 weeks of age (Walker and Kember 1972), this corresponds in this 
study with day 31 after screw implantation. When comparing bone resorption with formation in the 
Control-group, it can be seen that, beside the early bone formation peak, the BRR clearly exceeded the BFR 
in all bone regions most of the time and leveled out only towards the end of the study. This imbalance 
resulted in a steady bone loss in the bone-remodeling-zone as can be seen in the diminishing BV/TV in the 
control animals.  
The Gel-group did not show any statistically different results compared to the Control-group, therefore the 
chosen hydrogel can be considered not to have any influence on peri-implant bone remodeling. It was 
resorbed completely during the study without leaving any visible residuals, as confirmed by histology. 
The locally delivered Zoledronate interfered with the normal healing and remodeling process at a very early 
stage as demonstrated in the Zol-Gel-group. An increase of up to 100 % of the BFR was seen from days 3 to 
17 in the bone-healing-zone and from days 3 to 10 in the bone-remodeling-zone. Later on during the study, 
no more differences could be detected between the groups. This result suggests that Zoledronate is only 
influencing bone formation during the first “flush” with the drug where bone forming cells are either in 
contact with the gel or exposed to Zoledronate in solution. The direct contact could allow them to 
incorporate the drug via fluid phase endocytosis, an uptake mechanism for Zoledronate that has been 
described by Thompson et al. (Thompson, Rogers et al. 2006). BPs are known to be rapidly cleared from the 
circulation and absorbed to bone mineral surface (Lin 1996). The fast uptake in the bone can explain why 
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no further Zoledronate effect on bone formation could be detected later on in the study. This is because 
osteoclasts are the only cells that can liberate and incorporate BPs once they are bound to bone mineral 
(Rogers, Gordon et al. 2000). It remains unclear if the initial boost in bone formation is caused by a direct 
stimulation of the osteoblast activity, or by unknown indirect coupling effects. Arnoldi et al. recently found 
a higher level of cellular proliferation and osseous differentiation at an early time point around implants 
coated with fibrinogen and loaded with a very low dose of Zoledronate (Arnoldi, Alves et al. 2014). This 
finding supports the theory that Zoledronate can have a direct anabolic effect on bone formation. 
Published in vitro studies are not conclusive as they demonstrate that Zoledronate can have positive as well 
as negative results on osteoblasts, depending on the dose and study design (Pan, To et al. 2004; Greiner, 
Kadow-Romacker et al. 2006; Walter, Klein et al. 2010). Orriss et al. showed that the Zoledronate dose has 
to be increased 10- to 100-fold to achieve the same inhibitory effect on osteoblasts when those are 
cultured on dentin slides, a finding that supports the theory that absorbed BPs are significantly less 
effective on osteoblasts (Orriss, Key et al. 2009).  
Since Zoledronate is an anti-resorptive agent, the drug is expected to mainly influence bone resorption. In 
the present study, this was shown by the significantly reduced BRR in the drug treated animals. The strong 
resorption peak seen in the Control-group was not at all present in the bone-healing-zone of the Zol-Gel-
group in which the BRR remained at a constant low level. A slightly higher but still constant BRR level could 
be found in the bone-remodeling-zone of the Zol-Gel-group. The investigated time period was too short to 
detect a clear end of the drug effect on bone resorption. However, static and dynamic bone parameters of 
the last analyzed time points and periods suggested a diminishing drug effect with a slightly increasing BRR 
and decreasing differences between the groups, particularly in the bone-remodeling-zone. 
Looking at the spatial effect of the locally delivered Zoledronate, this study revealed that the majority of 
the effects of BPs occur at a distance of up to 736 µm around the screw, which corresponds to the earlier 
defined bone-healing-zone. Tests with hydrogel loaded with hydroxyapatite-particles (size 200 nm) that 
give the gel a light radiopacity (data not shown) revealed that the gel is located within a range of 0 - 600 µm 
around the screw. Therefore, it can be assumed that bone is in direct contact with the Zoledronate-loaded 
gel within the region that shows the strong drug effect. These results suggest that it may be possible to 
control the range of action of the Zoledronate-loaded gel via its penetration depth in bone. This is a 
promising approach as the penetration depth can be adapted by altering the mechanical properties of the 
gel or the volume of gel inserted into the implant bed. However, a significantly weaker drug effect was also 
shown for the bone-remodeling-zone that is not in contact with the gel. This finding suggests that a small 
part of the released Zoledronate diffuses through the bone despite its high affinity to mineral and its fast 
absorption in bone surfaces.  
The boost in initial bone formation, the effective inhibition of the bone resorption in the bone-healing-
zone, and the stabilization of the bone loss in the bone-remodeling-zone resulted in a BV/TV that was up to 
300 % higher compared to the Control-group in the bone-healing-zone and up to 100 % higher in the bone 
remodeling-zone. The reduction of SMI and Tb.Sp as well as the increase Tb.N confirmed a shift from 
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osteoporotic towards a more normal bone structure. This is a very positive finding as an augmented 
microstructure of peri-implant bone is linked to improved implant anchorage (Yakacki, Poukalova et al. 
2010; Wirth, Goldhahn et al. 2011; Wirth, Müller et al. 2012). The gain in bone volume and therefore in 
mechanical resistance might nevertheless be partly compensated for by the less mature bone structure 
that was present 2 months after screw implantation, as confirmed by histology in the present study. The 
SMI of 0.6 that characterized the bone in the bone-healing zone of the Zol-Gel-group at day 58 compared to 
an SMI of 2.6 in the Control-group confirmed that the very compact woven bone had not yet remodeled. 
Findings in similar studies provide enough evidence to show that Zoledronate treated bone can enhance 
implant fixation despite the reduced mechanical competence of the immature bone structure (Tengvall, 
Skoglund et al. 2004; Peter, Gauthier et al. 2006; Andersson, Agholme et al. 2010). Furthermore, Amanat et 
al. showed with an indentation study that Zoledronate has no influence on the intrinsic mechanical 
properties of healing bone (Amanat, He et al. 2008). 
The present study has inherent limitations. The microCT-based dynamic histomorphometry averages bone 
formation and resorption rate over the time period between two scans which makes the results sensitive to 
the chosen time points for the scans (Schulte, Lambers et al. 2011). In this study bone formation and bone 
resorption have to be interpreted as gain and loss of mineralized bone tissue since the microCT cannot 
analyze the bone on a cellular level. Furthermore, the age of the rats was not ideal due to the fact that the 
end of the initial OVX related bone loss phase and the cessation of bone length growth occurred during the 
experimental phase. Furthermore, in future studies, histology should be performed at early time points for 
a better understanding of how Zoledronate enhances very early peri-implant bone formation. It might also 
be useful to prolong the experimental phase in order to assess when bone maturity is reached in the Zol-
Gel-group. In this study, only one drug dose of 5 µg per implant was tested. A future dose-response study 
could help to investigate the dose-dependency of the present findings.  
In summary, the quickly degradable hydrogel used in this study appeared to be a very suitable drug delivery 
system for BPs. The texture and material properties of the gel allowed for an easy and precise application, 
combined with a deep penetration of the bone tissue that significantly increased the range of action of the 
drug. Numerous studies have shown that BPs released from coatings stay highly localized and result in a 
very thin layer of dense bone around implants which is not ideal for implant fixation (Stadelmann, Gauthier 
et al. 2008; McKenzie, Dennis Bobyn et al. 2011). This is not the case in the present study where an 
increased bone volume could be shown all over the analyzed trabecular region. The present study also 
demonstrated a positive influence of Zoledronate on early bone formation in addition to its known anti-
resorptive action. This effect seems to be supported by a fast release of the small BP molecules from the 
highly porous hydrogel, another point in favor of the use of hydrogels as drug-delivery systems for BPs. 
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 Conclusion 2.6
The present study was able to show that Zoledronate delivered from a quickly degrading hydrogel can 
boost early bone formation and later on efficiently inhibit peri-implant bone resorption close to an implant. 
It can also stabilize bone loss away from an implant in an OVX rat model. This process significantly 
enhanced bone mass and improved bone micro-structure in the treated peri-implant bone during the two 
months post-implantation that were studied. A reinforced bone structure is directly linked to improved 
implant fixation. The presented approach using Zoledronate-loaded hydrogel for implant bed preparation is 
highly promising, especially for patients suffering from low quality bone, though more studies are needed. 
 Acknowledgment 2.7
Special thanks to Sandra Jaccoud at the LBO for her assistance during surgeries and for the preparation of 
the histology slides. Thanks to Caroline Sieger Fernandes for the English proofreading of the manuscript. 
We benefited from the help of Prof. Brigitte von Rechenberg, Dr. Karina Klein and Dr. Salim Darwiche at the 
University of Zurich for the interpretation of the histology slides. This study was partially supported by a KTI 
grant (Project no. 11098.1). 
  
Investigation of the Effect of Locally Delivered Zoledronate on Peri-Implant Bone 
58 
 References 2.8
Alghamdi, H. S., R. Bosco, et al. (2013). "Osteogenicity of titanium implants coated with calcium phosphate or collagen 
type-I in osteoporotic rats." Biomaterials 34(15): 3747-3757. 
Allen, M. R., H. Follet, et al. (2006). "Antiremodeling agents influence osteoblast activity differently in modeling and 
remodeling sites of canine rib." Calcif Tissue Int 79(4): 255-261. 
Amanat, N., L. H. He, et al. (2008). "The effect of zoledronic acid on the intrinsic material properties of healing bone: 
an indentation study." Med Eng Phys 30(7): 843-847. 
Andersson, T., F. Agholme, et al. (2010). "Surface immobilized zoledronate improves screw fixation in rat bone: a new 
method for the coating of metal implants." J Mater Sci Mater Med 21(11): 3029-3037. 
Arnoldi, J., A. Alves, et al. (2014). "Early tissue responses to zoledronate, locally delivered by bone screw, into a 
compromised cancellous bone site: A pilot study." BMC Musculoskeletal Disorders 15(1). 
Astrand, J. and P. Aspenberg (2004). "Topical, single dose bisphosphonate treatment reduced bone resorption in a rat 
model for prosthetic loosening." J Orthop Res 22(2): 244-249. 
Åstrand, J., A. K. Harding, et al. (2006). "Systemic zoledronate treatment both prevents resorption of allograft bone 
and increases the retention of new formed bone during revascularization and remodelling. A bone chamber 
study in rats." BMC Musculoskeletal Disorders 7. 
Back, D. A., S. Pauly, et al. (2012). "Effect of local zoledronate on implant osseointegration in a rat model." BMC 
Musculoskeletal Disorders 13. 
Belfrage, O., H. Isaksson, et al. (2012). "Local treatment of a bone graft by soaking in zoledronic acid inhibits bone 
resorption and bone formation. A bone chamber study in rats." BMC Musculoskeletal Disorders 13. 
Bergman, K., T. Engstrand, et al. (2009). "Injectable cell-free template for bone-tissue formation." Journal of 
Biomedical Materials Research - Part A 91(4): 1111-1118. 
Bobyn, J. D., R. Thompson, et al. (2014). "Local alendronic acid elution increases net periimplant bone formation: A 
micro-CT analysis." Clin Orthop Relat Res 472(2): 687-694. 
Boyce, B. F., E. Rosenberg, et al. (2012). "The osteoclast, bone remodelling and treatment of metabolic bone disease." 
European Journal of Clinical Investigation 42(12): 1332-1341. 
Brouwers, J. E. M., F. M. Lambers, et al. (2008). "Bone degeneration and recovery after early and late bisphosphonate 
treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography." Calcif Tissue Int 
82(3): 202-211. 
Brouwers, J. E. M., B. Van Rietbergen, et al. (2007). "No effects of in vivo micro-CT radiation on structural parameters 
and bone marrow cells in proximal tibia of wistar rats detected after eight weekly scans." Journal of 
Orthopaedic Research 25(10): 1325-1332. 
Cheng, T. L., C. M. Murphy, et al. (2013). "Local delivery of recombinant human bone morphogenetic proteins and 
bisphosphonate via sucrose acetate isobutyrate can prevent femoral head collapse in Legg-Calve-Perthes 
disease: a pilot study in pigs." Int Orthop 38(7): 1527-1533. 
Cottrell, J. A., F. M. Vales, et al. (2010). "Osteogenic activity of locally applied small molecule drugs in a rat femur 
defect model." J Biomed Biotechnol 2010: 597641. 
Ferretti, M., C. Palumbo, et al. (2002). "Static and dynamic osteogenesis: Two different types of bone formation." 
Anatomy and Embryology 206(1-2): 21-29. 
Franchi, M., E. Orsini, et al. (2004). "Osteogenesis and morphology of the peri-implant bone facing dental implants." 
TheScientificWorldJournal [electronic resource]. 4: 1083-1095. 
Fuchs, R. K., R. J. Phipps, et al. (2008). "Recovery of trabecular and cortical bone turnover after discontinuation of 
risedronate and alendronate therapy in ovariectomized rats." Journal of Bone and Mineral Research 23(10): 
1689-1697. 
Futami, T., N. Fujii, et al. (2000). "Tissue response to titanium implants in the rat maxilla: Ultra structural and 
histochemical observations of the bone-titanium interface." Journal of Periodontology 71(2): 287-298. 
Gasser, J. A., P. Ingold, et al. (2008). "Long-term protective effects of zoledronic acid on cancellous and cortical bone in 
the ovariectomized rat." J Bone Miner Res 23(4): 544-551. 
Giuliani, N., M. Pedrazzoni, et al. (1998). "Bisphosphonates stimulate formation of osteoblast precursors and 
mineralized nodules in murine and human bone marrow cultures in vitro and promote early 
osteoblastogenesis in young and aged mice in vivo." Bone 22(5): 455-461. 
Greiner, S., A. Kadow-Romacker, et al. (2006). "The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant 
coating on osteoblasts in vitro." J Biomed Mater Res A 80(4): 769-775. 
Hildebrand, T. and P. Rüegsegger (1997). "Quantification of bone microarchitecture with the structure model index." 
Computer Methods in Biomechanics and Biomedical Engineering 1(1): 15-23. 
Investigation of the Effect of Locally Delivered Zoledronate on Peri-Implant Bone 
59 
Hilding, M. and P. Aspenberg (2007). "Local peroperative treatment with a bisphosphonate improves the fixation of 
total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients." Acta Orthop 
78(6): 795-799. 
Hogan, H. A., S. P. Ruhmann, et al. (2000). "The mechanical properties of cancellous bone in the proximal tibia of 
ovariectomized rats." Journal of Bone and Mineral Research 15(2): 284-292. 
Idris, A. I., J. Rojas, et al. (2008). "Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule 
formation in vitro." Calcif Tissue Int 82(3): 191-201. 
Jakobsen, T., J. Baas, et al. (2010). "The effect of soaking allograft in bisphosphonate: a pilot dose-response study." 
Clin Orthop Relat Res 468(3): 867-874. 
Kisiel, M., A. S. Klar, et al. (2013). "Evaluation of Injectable Constructs for Bone Repair with a Subperiosteal Cranial 
Model in the Rat." PLoS ONE 8(8). 
Lin, J. H. (1996). "Bisphosphonates: a review of their pharmacokinetic properties." Bone 18(2): 75-85. 
Marco, F., F. Milena, et al. (2005). "Peri-implant osteogenesis in health and osteoporosis." Micron 36(7-8): 630-644. 
Martínez-Álvarez, C., B. González-Meli, et al. (2013). "Injection and adhesion palatoplasty: a preliminary study in a 
canine model." Journal of Surgical Research 183(2): 654-662. 
Martínez-Sanz, E., O. P. Varghese, et al. (2012). "Minimally invasive mandibular bone augmentation using injectable 
hydrogels." Journal of Tissue Engineering and Regenerative Medicine 6(SUPPL. 3): s15-s23. 
McKenzie, K., J. Dennis Bobyn, et al. (2011). "Bisphosphonate Remains Highly Localized After Elution From Porous 
Implants." Clin Orthop Relat Res 469(2): 514-522. 
Meyer, U., U. Joos, et al. (2004). "Ultrastructural characterization of the implant/bone interface of immediately loaded 
dental implants." Biomaterials 25(10): 1959-1967. 
Orriss, I. R., M. L. Key, et al. (2009). "Inhibition of osteoblast function in vitro by aminobisphosphonates." J Cell 
Biochem 106(1): 109-118. 
Pan, B., L. B. To, et al. (2004). "The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of 
human bone-derived cells in vitro." Bone 34(1): 112-123. 
Pazianas, M., C. Cooper, et al. (2010). "Long-term treatment with bisphosphonates and their safety in postmenopausal 
osteoporosis." Ther Clin Risk Manag 6: 325-343. 
Peter, B., O. Gauthier, et al. (2006). "Local delivery of bisphosphonate from coated orthopedic implants increases 
implants mechanical stability in osteoporotic rats." J Biomed Mater Res A 76(1): 133-143. 
Plotkin, L. I., S. C. Manolagas, et al. (2006). "Dissociation of the pro-apoptotic effects of bisphosphonates on 
osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs." Bone 39(3): 443-
452. 
Plotkin, L. I., R. S. Weinstein, et al. (1999). "Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and 
calcitonin." Journal of Clinical Investigation 104(10): 1363-1374. 
Probst, A. and H. U. Spiegel (1997). "Cellular mechanisms of bone repair." Journal of Investigative Surgery 10(3): 77-
86. 
Recker, R. R., P. D. Delmas, et al. (2008). "Effects of intravenous zoledronic acid once yearly on bone remodeling and 
bone structure." Journal of Bone and Mineral Research 23(1): 6-16. 
Riggs, B. L. and A. M. Parfitt (2005). "Drugs used to treat osteoporosis: The critical need for a uniform nomenclature 
based on their action on bone remodeling." Journal of Bone and Mineral Research 20(2): 177-184. 
Roelofs, A. J., K. Thompson, et al. (2006). "Molecular mechanisms of action of bisphosphonates: Current status." 
Clinical Cancer Research 12(20 PART 2): 6222s-6230s. 
Rogers, M. J., S. Gordon, et al. (2000). "Cellular and molecular mechanisms of action of bisphosphonates." Cancer 
88(12 Suppl): 2961-2978. 
Roshan-Ghias, A., J. Arnoldi, et al. (2011). "In vivo assessment of local effects after application of bone screws 
delivering bisphosphonates into a compromised cancellous bone site." Clin Biomech 26(10): 1039-1043. 
Russell, R. G., N. B. Watts, et al. (2008). "Mechanisms of action of bisphosphonates: similarities and differences and 
their potential influence on clinical efficacy." Osteoporos Int 19(6): 733-759. 
Schulte, F. A., F. M. Lambers, et al. (2011). "In vivo micro-computed tomography allows direct three-dimensional 
quantification of both bone formation and bone resorption parameters using time-lapsed imaging." Bone 
48(3): 433-442. 
Seeman, E. (2009). "Bone modeling and remodeling." Critical Reviews in Eukaryotic Gene Expression 19(3): 219-233. 
Srisubut, S., A. Teerakapong, et al. (2007). "Effect of local delivery of alendronate on bone formation in bioactive glass 
grafting in rats." Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 104(4): e11-
e16. 
Stadelmann, V. A., O. Gauthier, et al. (2008). "Implants delivering bisphosphonate locally increase periprosthetic bone 
density in an osteoporotic sheep model. A pilot study." Eur Cell Mater 16: 10-16. 
Investigation of the Effect of Locally Delivered Zoledronate on Peri-Implant Bone 
60 
Tengvall, P., B. Skoglund, et al. (2004). "Surface immobilized bisphosphonate improves stainless-steel screw fixation in 
rats." Biomaterials 25(11): 2133-2138. 
Thompson, K., M. J. Rogers, et al. (2006). "Cytosolic entry of bisphosphonate drugs requires acidification of vesicles 
after fluid-phase endocytosis." Molecular Pharmacology 69(5): 1624-1632. 
Tobias, J. H., J. W. M. Chow, et al. (1993). "3-Amino-1-hydroxypropylidine-1-bisphosphonate (AHPrBP) suppresses not 
only the induction of new, but also the persistence of existing bone-forming surfaces in rat cancellous bone." 
Bone 14(4): 619-623. 
Waarsing, J. H., J. S. Day, et al. (2004). "Detecting and tracking local changes in the tibiae of individual rats: A novel 
method to analyse longitudinal in vivo micro-CT data." Bone 34(1): 163-169. 
Walker, K. V. and N. F. Kember (1972). "Cell kinetics of growth cartilage in the rat tibia. II. Measurements during 
ageing." Cell and Tissue Kinetics 5(5): 409-419. 
Walter, C., M. O. Klein, et al. (2010). "Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic 
cells." Clin Oral Investig 14(1): 35-41. 
Watts, N. B. and D. L. Diab (2010). "Long-term use of bisphosphonates in osteoporosis." J Clin Endocrinol Metab 95(4): 
1555-1565. 
Wirth, A. J., J. Goldhahn, et al. (2011). "Implant stability is affected by local bone microstructural quality." Bone 49(3): 
473-478. 
Wirth, A. J., R. Müller, et al. (2012). "Augmentation of peri-implant bone improves implant stability: Quantification 
using simulated bone loss." Journal of Orthopaedic Research 30(2): 178-184. 
Yakacki, C. M., M. Poukalova, et al. (2010). "The effect of the trabecular microstructure on the pullout strength of 
suture anchors." J Biomech 43(10): 1953-1959. 
 
 
 61 
 Development of a Drug Delivery Chapter 3
System  
Paper 2 Combining a Locally Delivered Bisphosphonate with 
Hydroxyapatite Particles – Can We Achieve Synergistic Effects?  
 
  
Development of a Drug Delivery System 
62 
 Abstract 3.1
Locally applied Zoledronate has been shown in several studies to inhibit peri-implant bone resorption and 
recently also to enhance bone formation. Other studies have demonstrated positive effects of 
hydroxyapatite particles on peri-implant bone regeneration and an enhancement of the anti-resorptive 
effect of bisphosphonates by the presence of calcium. Therefore an increase of the positive Zoledronate 
effect on early bone formation was assumed for a combined release of Zoledronate and hydroxyapatite 
nanoparticles (nHA). Possible synergistic effects were first investigated in vitro in a RAW 264.7 cell assay 
and then in vivo in a rat model of postmenopausal osteoporosis. The in vitro study confirmed that the 
inhibitory effect of Zoledronate on murine macrophages was enhanced by loading the drug on nHA. For the 
in vivo investigation, Zoledronate-loaded nHA or nHA were integrated in hyaluronic acid hydrogel and 
applied in the screw holes in rat femoral condyles before insertion of miniature screws. MicroCT based 
dynamic histomorphometry and histology revealed an unexpected rapid mineralization of the hydrogel in 
vivo through formation of granules which served as scaffold for new bone formation. The delivery of 
Zoledronate-loaded nHA further inhibited a degradation of the mineralized hydrogel as well as a resorption 
of the peri-implant bone to a similar extent than Zoledronate without nHA. The rapid in vivo mineralization 
combined with the inhibitory effect of Zoledronate on bone resorption and biomaterial degradation is 
highly interesting. However, the microCT based study did not allow us to distinguish between 
forming/resorbing bone and mineralizing/degrading biomaterial, preventing a possibility to evaluate in vivo 
synergistic effects on bone remodeling. Hyaluronic acid with Zoledronate-loaded nHA, thanks to its dual 
effect on inducing mineralization and preventing resorption, is nevertheless a very promising and versatile 
material for bone repair and augmentation. 
Keywords: Drug delivery; hydrogel; hydroxyapatite; bisphosphonate; microCT; biomaterial mineralization 
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 Introduction 3.2
Zoledronate-loaded hyaluronic acid hydrogel has recently been shown to efficiently improve early bone 
formation and inhibit bone resorption around an implant in a rat model of postmenopausal osteoporosis 
(chapter 2). This is an important finding as a sufficient peri-implant bone density is directly linked to a 
successful implant fixation (Stromsoe, Kok et al. 1993; Wilmes, Rademacher et al. 2006; Wirth, Goldhahn et 
al. 2011). A reliable implant anchorage is however often difficult to achieve in patients suffering from bone 
diseases that are characterized by a reduced bone density, such as osteoporosis. Implant migration and 
revision surgeries are often the consequence in those cases (Lobo-Escolar, Joven et al. 2010). Therefore the 
local delivery of a bisphosphonate (BP) to the peri-implant bone stock, as demonstrated with the drug-
loaded hydrogel (chapter 2), is a very promising approach to improve the outcome of implant fixation in 
patients presenting low bone quality.  
In parallel, other strategies have been proven to be able to successfully improve implant anchorage. One of 
them is the application of hydroxyapatite (HA) particles to the implant bed. Tami et al. demonstrated that 
HA-particles that are filled in a screw hole are able to induce and maintain a denser bone mantle in 
osteoporotic bone (Tami, Leitner et al. 2009). HA is chemically similar to the inorganic components of the 
bone matrix and therefore exhibits an excellent biocompatibility with soft and hard tissues (Zhou and Lee 
2011). It is known to be bioactive, osteoconductive and biodegradable and therefore it is widely used as 
biomaterial for dental and orthopedic applications (LeGeros 2008). Considering also the fact that Ca2+ ions 
have been shown to enhance the inhibitory effect of nitrogen-containing BPs on macrophages by 
enhancing their endocytic internalization in vitro (Monkkonen, Taskinen et al. 1994; Thompson, Rogers et 
al. 2006), it can be assumed that a combination of BPs and calcium phosphate particles may induce 
synergetic effect on bone remodeling.  
So far BPs have mainly been absorbed on HA bulk implants or coatings using the high affinity of the drug to 
mineral (Yoshinari, Oda et al. 2002; Peter, Gauthier et al. 2006; Suratwala, Cho et al. 2008; Faucheux, 
Verron et al. 2009; Sörensen, Arnoldi et al. 2013). Binding BPs to bulk hydroxyapatite is associated with a 
slow release of the drug as a low pH is required for a spontaneous release of the drug from a mineral 
surface (Rogers, Gordon et al. 2000; Nancollas, Tang et al. 2006). However, as shown in our previous work, 
a fast availability of the BP seems to be important for a positive effect on early bone formation (chapter 2). 
Therefore it would be favorable to combine the BP with small enough HA-particles that could be distributed 
easily in bone and be uptaken by osteoclasts.  
Several studies have investigated the applicability of bisphosphonate-loaded nanoparticles for antitumor 
drug delivery properties (Palazzo, Iafisco et al. 2007) and for intravenous drug delivery systems (Ong, Loo et 
al. 2008). Boanini et al. showed that Zoledronate-HA nano-composites promote osteoclast formation and 
osteoclast apoptosis in vitro, but they did not publish comparative results with pure Zoledronate (Boanini, 
Torricelli et al. 2012). Nejadnik et al. demonstrated recently that bisphosphonate-functionalized hyaluronic 
acid containing calcium phosphate particles is stable in vivo and attracts bone ingrowth (Nejadnik, Yang et 
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al. 2014). This study however used Pamidronate as chemical link between calcium phosphate particles and 
the hydrogel matrix (Wang, Zhang et al. 2006). Contrary to the present work, a release of the drug to the 
bone was not intended and expected to be minimal (Nejadnik, Yang et al. 2014). 
In present study we investigate in vitro in cell assays and in vivo in an osteoporotic rat model if we can 
achieve synergistic effects on peri-implant bone remodeling by adding osteoconductive hydroxyapatite 
nano-sized particles loaded with Zoledronate to hyaluronic acid hydrogel.  
 Materials and Methods 3.3
Zoledronate used for this study was bought from Enzo Life Sciences (Art.-Nr. ALX-430-153-0000, Enzo Life 
Sciences, Farmingdale, USA). Hydroxyapatite powder (nHA) with a particle size around 200 nm was bought 
from Sigma (art-nr. 677418, Sigma-Aldrich, St. Louis, MO, USA). Those particles have a round shape (Figure 
3.1). The nHA-particles were heat sterilized before use. Cell culture medium (CCM) for the in vitro studies 
was prepared by mixing Dulbecco’s Modified Eagle Medium (DMEM, art.-nr. 41966-029, Gibco, Life 
Technologies, Carlsbad, CA, USA) with 10% fetal bovine serum (Sigma-Aldrich, art.-nr. F7524-500ML) and 
1% penicillin/streptomycin (art.-nr. 15140122, Gibco) and 1% L-glutamine (art.-nr. 25030024, Gibco). 
 
Figure 3.1:   Scanning electron microscope image of the hydroxyapatite nanoparticles used for the present study. 
3.3.1 In vitro Cell Assay 
Murine macrophages (RAW 264.7, passage 13-16) were used for the present study as those cells have been 
shown to react in vitro to bisphosphonate exposure in a similar way than osteoclasts and to tolerate well 
the presence of HA-particles (Scheel, Weimans et al. 2009; Abe, Yoshimura et al. 2012).  
An aqueous Zoledronate solution with a concentration of 2 mg/ml was prepared and sterile filtered. The 
drug solution was diluted with CCM to a final concentration of 80 μM of Zoledronate. A dilution series with 
CCM resulted in Zoledronate supplemented medium (Zol-CCM) with concentrations from 80 μM to 0.625 
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μM. The dilution procedure was repeated with an aqueous dispersion containing 2 mg/ml Zoledronate and 
20 mg/ml nHA (nHA-Zol-CCM), and a dispersion containing only 20 mg/ml nHA (nHA-CCM). 
Macrophages were seeded with a density of 2500 cells per well in 96-well plates (Microtest™ 96, Becton 
Dickinson Labware, NJ, USA) using 6 wells per group and incubated with 100 µl CCM at standard incubation 
conditions (37°C, 5% CO2). After 24 h of incubation, 100 µl of CCM, Zol-CCM, nHA-Zol-CCM or nHA-CCM 
were added to the cells. The experimental groups of the three assays are listed in Table 3.1. A cell 
proliferation test (CellTiter 96® AQueous One Solution, Promega, Fitchburg, WI, USA) was performed after 
24, 48 and 72 hours of cell exposure to the modified CCM. The absorbance was measured with a plate 
reader (Wallac 1420 Victor 2, Perkin Elmer, Waltham, MA, USA). Background plates with modified media 
only were measured at all time points to avoid a bias caused by nHA-particles in the dispersions. Untreated 
cells served as control for a normalization of the absorbance results. 
Group 1 2 3 4 5 6 7 8 9  
Zoledronate -
Assay 
0.16 0.31 0.63 1.25 2.5 5 10 20 40 Zol-concentration [μM] 
- - - - - - - - - nHA-concentration [μg/ml] 
nHA-
Zoldedronate-
Assay 
0.16 0.31 0.63 1.25 2.5 5 10 20 40 Zol-concentration [μM] 
0.04 0.09 0.17 0.34 0.68 1.36 2.72 5.44 10.88 nHA-concentration [μg/ml] 
nHA-Assay 
- - - - - - - - - Zol-concentration [μM] 
0.04 0.09 0.17 0.34 0.68 1.36 2.72 5.44 10.88 nHA-concentration [μg/ml] 
Table 3.1:   Experimental groups of the 3 cell assays: Zoledronate and nHA concentration in the CCM are given for each group, each 
assay was complemented with a control group that is not mentioned in the table. 
3.3.2 Hydrogel Preparation 
Commercially available cross-linked hyaluronic acid (Termira AuxiGel™, Stockholm, Sweden) was used as 
the drug delivery system for the BP. This gel has already been shown to be a suitable drug delivery system 
for bisphosphonates (chapter 2). The preparation of the hydrogel was done under sterile conditions in a 
laminar flow chapel. An aqueous solution containing 2 mg/ml Zoledronate was prepared and sterile 
filtered. nHA-particles were added to the solution with a nHA/Zoledronate ratio of 100:1. The exact drug 
dose was ensured by mixing precisely weighed and measured amounts of Zoledronate, nHA, and distilled 
water. Crosslinking of the hydrogel was achieved by mixing a hyaluronan derivative (component A) with a 
PVA cross-linker (component B). Five parts of the Zoledronate/nHA solution were mixed with 3 parts 
component A and 2 parts component B for the nHA-Zol-Gel-group. The Zoledronate-nHA dispersion was 
replaced by bi-distilled water with nHA for the nHA-Gel-group. The resulting gels were allowed to settle for 
1 h before filling the capillary pistons of a positive displacement pipette (Microman®, Gilson, Middleton, 
USA) with 5 μl gel each. The capillaries were pulled off the pipette with the gel inside and left 1 h for 
settling. Then they were sterile packed in plastic tubes and frozen at -20°C.  
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3.3.3 Drug Release Study 
The release of Zoledronate from hydrogel containing nHA-particles and pure hydrogel was assessed 
indirectly with a cell assay. Zoledronate-loaded hydrogel was prepared with and without nHA following the 
technique described in 4.2. The gels were incubated for 1 h in bi-distilled water at room temperature. The 
ratio of water and gel was 3:1 to reach a total concentration of 250 μg per 1 ml liquid/gel volume. For 
comparison, an aqueous Zoledronate solution with a concentration of 250 μl/l was also prepared (Figure 
3.2). The Zoledronate solution was sterile filtered and diluted in CCM to reach final concentrations of 10 
μM, 5 μM, and 0.625 μM. The supernatant received from the hydrogel incubation was diluted similarly. 
RAW 264.7 cells were prepared as described in 4.1. After 24 h of incubation in CCM, 100 µl of the prepared 
media were added, the final concentrations of Zoledronate were therefore 5 μM, 2.5 μM and 0.3125 μM. A 
cell proliferation assay was performed after 24, 48 and 72 hours of incubation with Zoledronate. 
 
Figure 3.2:   Preparation of the indirect release study using a RAW 264.7 macrophages cell assay. The drug-loaded hydrogel with 
and without nHA was incubated in H2O during 1 h to investigate if a burst release of the drug occurs. Macrophages were later 
exposed to the supernatants of the hydrogels that were highly diluted with cell culture medium. 
3.3.4 In vivo Study 
An in vivo study in a rat femoral model of postmenopausal osteoporosis was performed following a 
protocol that was established and published earlier by our group (chapter 2). All animal procedures were 
approved by the local animal care and use committee (license no. 2508.1, EXPANIM, SCAV, Epalinges, 
Switzerland).  
Surgical Procedures 
Eight virgin female Wistar rats (Janvier Labs, Saint-Berthevin, France) were ovariectomized bilaterally with a 
dorsal approach (Alghamdi, Bosco et al. 2013) at an age of 17 weeks and a weight of 295±18 g to induce an 
estrogen deficiency related bone loss (Hogan, Ruhmann et al. 2000). The rats were housed 4 per cage 
under 12 h light to 12 h dark cycles at 22°C room temperature with 55% humidity. They were fed a 
standard rodent diet (KLIBA NAFAG 3436, Provimi Kliba AG, Switzerland) and tap water at libitum. After 
ovariectomy (OVX) of the rats, food intake was limited to 50 g per kg body weight per day. Sterilized hay, 
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paper tunnels and wooden sticks were offered as cage environment enrichment. Animals were fed in 
groups, therefore an equal nutrition of all animals was ensured by a close monitoring and regular weighing.  
Miniature screws were implanted bilaterally into the femoral condyles of 22 weeks old rats with a mean 
weight of 350±20 g. The screws with a thread length of 3 mm and a diameter of 1.4 mm were custom made 
from radiopaque polyetheretherketone (PEEK) (RISystem, Davos, Switzerland) and coated with a 100 nm 
titanium layer to mimic the interface with a standard orthopedic screw. Before screw insertion, the pre-
drilled unicortical screw holes (diameter 1.2 mm, depth 3.5 mm) were filled with 5 µl of the prepared 
hydrogel containing only nHA (nHA-Gel-group) or nHA and 5 µg of Zoledronate (nHA-Zol-Gel-group) with a 
positive displacement pipette. Both legs of each animal were treated with the same hydrogel to avoid an 
unwanted drug effect on the contralateral side. 
In vivo microCT Imagine and Image Processing 
In vivo microCT scans (Skyscan 1076, Bruker microCT, Kontich, Belgium) of the right femur only were 
performed one day before OVX and one day before screw implantation in order to confirm the bone loss 
caused by the estrogen deficiency. Both femurs were then scanned at day 3, 10, 17, 31, 45, and 58 after 
screw implantation for the dynamic histomorphometry. The parameters for data acquisition and 
reconstruction were chosen according to our published protocol (chapter 2). The animals were kept under 
Isoflurane anesthesia during the scanning time to avoid motion artifacts. All rats were sacrificed at the time 
of the last microCT scan with Pentobarbital (Esconarkon, Streuli Pharma SA, Uznach) while being under 
anesthesia.  
The image taken for the evaluation of the bone loss and for dynamic histomorphometry were processed 
and analyzed using the software Amira® (FEI Visualization Sciences Group, Burlington, USA) and CTan 
(Bruker microCT) as published earlier (chapter 2). Dynamic histomorphometry is an image processing 
technique based on a registration and comparison of consecutive microCT scans (Waarsing, Day et al. 2004; 
Roshan-Ghias, Lambers et al. 2011; Schulte, Lambers et al. 2011). Mineralized tissue volume that is present 
only on the first microCT scan is considered as being resorbed/degraded, whilst that present only on the 
second scan is considered as newly mineralized tissue/formed bone. For an analysis of the spatio-temporal 
effect, the static and dynamic bone parameters were analyzed in concentric 4 layers of 368 µm each 
around the screw. This partition has been shown to furnish useful information of the peri-implant bone 
remodeling (chapter 2). 
3.3.5 Histology 
The rat femurs were dissected just after sacrifice at week 58 after screw implantation and fixed, 
dehydrated and embedded in PMMA following a protocol that we published elsewhere (chapter 2). After 
polymerization, the sections were cut, glued to PMMA slides and polished before etching their surface with 
0.7 % formic acid (Applichem, Gatersleben, Germany) and staining them with Giemsa (VWR, Dietikon, 
Switzerland) or Toluidine Blue (Promega, Fitchburg, WI, USA). Microscopy images for evaluation were taken 
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using an upright microscope (DM 5500, Leica Microsystems, Wetzlar, Germany). The ground sections were 
finally X-rayed (Skyscan 1076, Bruker microCT) for a mapping of the tissue density. 
3.3.6 Statistics 
Statistical testing was done with Matlab (Mathworks, Natick MA, USA). The Mann-Whitney U-test was used 
to test for statistical differences in the cell culture results as normal distribution was not always given. The 
static and dynamic mineralized tissue parameters were tested for significance with a non-parametric 
Kruskal Wallis ANOVA followed by a Tukey's HSD (Honestly Significant Difference) test as normal 
distribution and equal variance were not given for all groups. Values lying outside an interval of 1.5 times 
the quartile range were identified as outliers and excluded. 
 Results 3.4
3.4.1 Cell Assay 
A visual inspection of the RAW 264.7 murine macrophages via microscopy revealed that those cells are 
capable of incorporating large amounts of the nanoparticles that were used for the present study (Figure 
3.3). This way, they were able to remove all particles in their direct surrounding. 
 
Figure 3.3:   Light microscopy images of RAW 264.7 murine macrophages after 72 h of incubation with (bottom) and without (top) 
nHA, the macrophages are able to incorporate large amounts of particles (red arrows), this way they “clean up” all the particles in 
their direct surrounding (image bottom left). 
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When looking on the proliferation of the macrophages incubated with different concentrations of nHA-
particles dispersed in the CCM, it could be seen that the HA is well tolerated by the cells as no significant 
drop of the proliferation can be detected at any time and concentration (Figure 3.4). This results is in good 
agreement with published data demonstrating that RAW 264.7 macrophages tolerate HA-particles with 
different sizes and shapes up to a concentration of 500 µg/ml (Scheel, Weimans et al. 2009). 
 
Figure 3.4:   Proliferation study with RAW 264.7 macrophages incubated with various concentrations of nHA-particles in the cell 
culture medium. The proliferation was measured after 24, 48 and 72 hours. The results from the nHA treated cells are displayed 
normalized by the results from untreated cells that served as control. 
When cultivated with different concentrations of Zoledronate, the RAW 264.7 macrophages showed a 
typical dose- and time- dependent proliferation decrease (Figure 3.5). This result confirms the findings of 
Abe et al. who showed earlier that nitrogen-containing bisphosphonates are cytotoxic for RAW 264.7 cells 
(Abe, Yoshimura et al. 2012).  
 
Figure 3.5:   Proliferation study with RAW 264.7 macrophages incubated with various concentrations Zoledronate in the cell culture 
medium. The proliferation was measured after 24, 48 and 72 hours. The results from the nHA treated cells are displayed 
normalized by the results from untreated cells that served as control. 
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In a third cell assay, the RAW 264.7 macrophages were incubated with Zoledronate-loaded nHA-particles. 
Again, a dose- and time-dependent decrease in the cell proliferation was seen (Figure 3.6). Interestingly, 
this decrease occurred significantly faster than in the cells treated pure Zoledronate (Figure 3.5). This 
finding indicates that the inhibitory effect of the bisphosphonate on macrophages in vitro is significantly 
more efficient when the Zoledronate is administered bound to hydroxyapatite nanoparticles. 
 
Figure 3.6:   Proliferation study with RAW 264.7 macrophages incubated with various concentrations Zoledronate-loaded nHA-
particles in the cell culture medium. The proliferation was measured after 24, 48 and 72 hours. The results from the Zoledronate-
nHA treated cells are displayed normalized by the results achieved from untreated cells that served as control. Statistical significant 
differences to the cell assay with equal amounts of pure Zoledronate (Figure 3.5) are indicated. The two highest concentrations 
were not considered as the measured results did not correlate with the visual inspection of the cells (only dead cells visible after 
48/72 h). The absorbance readings might have been biased by the presence of large quantities of nHA-particles. 
3.4.2 Drug Release Study 
The cell proliferation test with murine macrophages only allowed a functional estimation of the early 
passive release from the hyaluronic acid hydrogel. The drug concentration in the medium of the two 
release groups (Zol-Gel, nHA-Zol-Gel) was estimated by comparing their cell proliferation with the 
reference group (Zol) where a known Zoledronate concentration had been used. When comparing the Zol-
Gel-group with the nHA-Zol-Gel group, we saw a clear difference between the cell proliferations (Figure 
3.7). By comparing the curves, it could be estimated that the final concentration of Zoledronate in the CCM 
of the Zol-Gel-group must have been around 75% (50%-100%) of the maximum possible concentrations 
that would have been seen if the drug would not at all have been retained by the hydrogel (Zol-group). This 
result confirms the assumption that the highly porous hydrogel delivers the small Zoledronate molecules 
via a burst release. In contrary, the cells exposed to diluted nHA-Zol-Gel-supernatant did not show a 
significant difference to untreated cells at any time and any concentration. This result suggests that no 
significant amount of drug was released during the first hour of incubation in water. However, as the 
supernatant was filtered before adding it to the CCM, it can only be concluded that no Zoledronate was in 
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solution after 1 hour of incubation in H2O. It is still possible that nHA-particles loaded with the drug have 
been released and were later on removed during the sterile filtering. 
 
Figure 3.7:   Results for the RAW 264.7 cell assay investigating the Zoledronate release from hydrogels during 1 h of incubation in 
water. RAW 264.7 cells were cultivated for 24-72 hours. The results from the Zoledronate-treated cells are displayed normalized by 
the results achieved from untreated cells that served as control. Zol1-3 marks the cells that were exposed to a known concentration 
of Zoledronate (in brackets). Zol-Gel 1-3 and nHA-Zol-Gel 1-3 mark cells that were exposed to the supernatant with unknown 
Zoledronate concentration received from the hydrogel incubation. 
3.4.3 In vivo Study 
All rats tolerated both surgeries well and returned to normal activity right after surgery. The limited food 
intake allowed a controlled weight gain of the animals; their final mean weight was 384±24 g. Analysis of 
the bone parameters based on the microCT scans performed before and after ovariectomy confirmed a 
successful ovariectomy by showing a bone loss in all animals similar to the results found before in this 
model (chapter 2). 
MicroCT-based Dynamic Histomorphometry 
A total of 87 microCT scans were analyzed for the dynamic histomorphometry as 3 had to be excluded due 
to motion artefacts. One leg of one animal from the nHA-Zol-Gel-group showed an excessive bone 
formation that was identified as outlier and therefore excluded. Five to eight samples were left in each 
group after removal of the outliers. The rapidity of the appearance and the structure of the mineralizing 
tissue that became visible on the microCT scans suggested that not only be formed bone was involved 
(Figure 3.8). Histology confirmed later that the hydrogel-nHA composite mineralized in vivo. As it is not 
possible to distinguish on the microCT scans between bone and hydroxyapatite, we anlyzed mineralization 
rate (MR) and demineralization rate (DR) instead of bone formation and bone resorption rates and 
mineralized tissue volume (MV) instead of bone volume (BV). 
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Figure 3.8:   MicroCT scans taken at 6 time points after surgery from the nHA-Gel-group (top), and the nHA-Zol-Gel-group (bottom). 
The images show a rapid mineralization of the tissue around the screws in both groups that is resorbed and remodeled quickly in 
the nHA-Gel-group and persists in the nHA-Zol-Gel-group. 
Static Parameters 
Only one static parameter, mineralized tissue fraction (MV/TV) was analyzed for this study as all other 
typical bone parameters would be misleading when looking at mixture of bone and mineralizing 
biomaterial. The results from this study were compared to the BV/TV of animals that were treated with 
Zoledronate-loaded hydrogel and pure hydrogel obtained in a previous study (chapter 2). This comparison 
was used to investigate synergistic effects between locally delivered nHA and Zoledronate as well as 
between hyaluronic acid hydrogel and nHA. The MV/TV values were normalized to the first microCT scan 
(day 3 after screw implantation) to rule out a bias caused by the nHA that was visible already on the scan of 
day 3 in the nHA-Gel-group and the nHA-Zol-Gel-group. The analysis of the MV/TV in the layer next to the 
screw surface (0-368 µm) showed no difference at any time between the nHA-Zol-Gel-group and the group 
that released the drug from pure hydrogel (Zol-Gel-group) (Figure 3.9). In the second layer (368-736 µm) 
the MV/TV gain was around 50% higher in the nHA-Zol-Gel-group than in the Zol-Gel-group starting from 
day 17. A large standard deviation however prevented a statistical significance of the results. This 
difference diminished to around 30% in the third layer (736-1104 µm), a significant difference could again 
not be shown due to a high variability of the results. No difference at all was visible in the fourth layer 
(1104-1472 µm). 
The results from the nHA-Gel-group were compared to the results of the Gel-group from the previous study 
(chapter 2). Close to the screw (0-368 µm), the nHA in the hydrogel caused a mineralized tissue fraction 
gain that was around 30% higher than in the Gel-group during the full experimental period. This difference 
was however not statistically significant. In the second layer (368-736 µm), the MV/TV doubled between 
day 3 and day 10, a development comparable to the Zoledronate-treated groups and significantly higher 
than in the Gel-group which showed a constant MV/TV. Later on, the difference between the two groups 
diminished and was only marginal at the end of the experimental period. A similar development was 
observed in the third layer, where the initial gain in MV/TV was only 50% and the difference between nHA-
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Gel-group and Gel-group equaled out by day 17. No difference between nHA-Gel-group and the Gel-group 
was found in the outermost layer (1104-1472 µm). 
 
Figure 3.9:   Mineralized volume/ tissue volume measured in 4 layers around the screw. The grey asterisks indicate the significant 
differences between nHA-Gel-group and Gel-group and the dollar signs indicate the significant differences between nHA-Zol-Gel-
group and nHA-Gel-group. The data from the Zol-Gel-group and the Gel-group were acquired during an earlier study (chapter 2) 
and are shown for comparison. 
Dynamic Parameters 
The analysis of the dynamic parameters gives information about bone formation and resorption processes. 
In the case of the present study, it is not clear which part of the appearing mineralized structure was new 
bone and which part was mineralizing biomaterial, therefore we measured a general mineralization rate 
instead of a bone formation rate. The same applied for the bone resorption rate, which was named 
demineralization rate for this study and included bone resorption and biomaterial degradation. A 3D 
rendering of a comparison of two consecutive microCT scans (Figure 3.10) gave a good overview over the 
mineralizing and demineralizing processes. It could be seen that in both groups there was a significant 
mineralization around the screw between day 3 and day 10, which was followed by a pronounced 
demineralization in the nHA-Gel-group. The bone further away from the implantation site, however, was 
gradually resorbed. The nHA-Zol-Gel-group, on the contrary, showed only very little demineralization in the 
analyzed region. Those findings were also represented in the measured mineralization and 
demineralization rate (Figure 3.11 and 3.12). 
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Figure 3.10:   Volume rendering of comparisons of always two consecutive microCT scans of two representative samples, one from 
the nHA-Gel-group (top) and one from the Zol-Gel-group (bottom). The analyzed trabecular region of the bone is displayed in 
opaque, the screw in dark grey and the cortex in transparent. 
No differences in the mineralization rate in direct contact with the screw (layer 0-368 µm) were found 
between the two groups from this study and the two groups without nHA from our previous study (Figure 
3.11). In the second layer (368-736 µm), however, between day 3 and day 10 there was a highly significant 
difference between the nHA-Gel-group and the Gel-group and a small trend to a higher mineralization rate 
in the nHA-Zol-Gel-group compared to the group that released the drug directly from the hydrogel (Zol-Gel-
group). Those differences equaled out by day 10. The same situation was present also in the outer two 
layers (736-1472 µm). 
When looking at the bone resorption/demineralization rate, we observed the typical difference between 
the Zoledronate and the non-Zoledronate groups (Figure 3.12). The bone resorption/demineralization peak 
between days 10 and 31 that is characteristic for the drug-free groups was completely inhibited by the 
locally delivered Zoledronate. The demineralization rate of the nHA-Zol-Gel-group did not differ at any time 
and in any region from the one of the Zol-Gel-group. When comparing the nHA-Gel-group with the Gel-
group, there was an unexpected trend to a higher demineralization rate in the nHA-group in the outer two 
layers (736-1472 µm). 
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Figure 3.11:   Mineralization rate including bone formation and biomaterial mineralization measured in 4 layers around the screw, 
the grey asterisks indicate the significant differences between nHA-Gel-group and Gel-group, and the dollar signs indicate the 
significant differences between nHA-Zol-Gel-group and nHA-Gel-group. The data from the Zol-Gel-group and the Gel group were 
acquired during an earlier study (chapter 2) and are shown only for comparison. 
 
Figure 3.12:   Demineralization rate including bone resorption and biomaterial degradation measured in 4 layers around the screw, 
the grey asterisks indicate the significant differences between nHA-Gel-group and Gel-group and the dollar signs indicate the 
significant differences between nHA-Zol-Gel-group and nHA-Gel-group. The data from the Zol-Gel-group and the Gel-group were 
acquired during an earlier study (chapter 2) and are shown only for comparison. 
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3.4.4 Histology 
The histological results confirmed the earlier finding that the used hyaluronic acid hydrogel is fully 
degraded after 58 days of implantation without leaving any visible residues (Figure 3.13 and 3.14). All 
screws showed a good osteointegration without any inflammation reaction or fibrotic tissue encapsulation. 
In both nHA-Gel- and nHA-Zol-Gel groups there were highly mineralized regions present within the bone. 
Those granule shaped spots had a diameter of up to 50 µm in the nHA-Gel-group and extended across wide 
areas in the nHA-Zol-Gel-group. The X-rays taken of the histology slides indicate that those granules can be 
denser than bone tissue. It can be excluded that those regions simply represent remaining nHA-particles as 
those particles have a diameter of less than 200 nm and the observed granules are much bigger.  
In the nHA-Gel group, only small amounts of those mineralized spots were found in islands of new bone 
located mainly close to the screw tip, the region where the hydrogel cumulates during screw insertion. The 
granules were completely embedded in the bone matrix and the resulting constructs showed a trabecular 
structure. Large amounts of multinucleated cells such as macrophages and giant foreign body cells were 
present in the bone marrow around these bone-mineralization islands indicating an on-going resorption of 
the mineralized hydrogel. No new bone formation could be detected in this group beside a thin layer close 
to the screw surface and the bone close to the biomaterial. Almost no trabecular bone was left around the 
screw in the nHA-Gel group 13 weeks after OVX.  
 
Figure 3.13:   Toluidine blue stained ground sections from the nHA-Gel-group (top) and the nHA-Zol-Gel-group (bottom). The yellow 
asterisks in the darker blue regions indicate immature, non-remodeled bone, the yellow ellipses on brighter blue regions mark 
remaining old bone. Mineralized hydrogel residues are highlighted with yellow crosses. The small black-and-white panels are X-rays 
of the histology slides and show the mineralization of each region. 
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The nHA-Zol-Gel-group showed a completely different situation. Significantly larger mineralized regions 
were found mainly close to the screw tip but also between the threads. The remaining mineralized 
biomaterial had a porous structure and was partly penetrated by bone tissue. In contrast to what was seen 
in the nHA-Gel-group, the bone-mineralization constructs were rather compact and did not show a 
trabeculae-like structure. Smaller amounts of macrophages but no giant foreign body cells could be 
detected in the bone marrow close to the biomaterial, which confirms the inhibiting effect of Zoledronate. 
In general, much more trabecular bone could be found around the screw in the nHA-Zol-Gel-group 
compared to the nHA-Gel group. New bone formed next to and away from the screw surface and especially 
also at the interface to the mineralized hydrogel. A significant periosteal callus formation was also seen in 
the nHA-Zol-Gel-group that was not present to this extent in the nHA-Gel-group. 
 
Figure 3.14:   Details from the samples shown in Figure 3.13 stained with Giemsa for a better differentiation between bone (pink) 
and mineralized hydrogel (pink-brownish). In the left image, small granule-shaped mineralized spots from the nHA-Gel-group are 
marked with yellow arrows. In the right one, an extended mineralized region from the nHA-Zol-Gel group is marked with a yellow 
line; smaller regions are also highlighted with yellow arrows. 
 Discussion 3.5
The main goal of the present study was to investigate if a synergistic effect can be achieved by adding 
hydroxyapatite nanoparticles to Zoledronate-loaded hydrogel. Such an effect can be presumed based on 
studies that showed enhanced peri-implant bone density after application of HA-particles, an increase of 
Zoledronate potency in presence of Ca+ ions and favorable bone ingrowth in bisphosphonate-linked 
hydrogel containing calcium phosphate particles (Monkkonen, Taskinen et al. 1994; Merrell, Wakchoure et 
al. 2007; Tami, Leitner et al. 2009; Nejadnik, Yang et al. 2014). The present study was based on a previous 
study showing that Zoledronate locally delivered from a hyaluronic acid hydrogel increases the early bone 
formation rate up to 100% while efficiently inhibiting peri-implant bone resorption (chapter 2). 
Astonishingly, the main finding of this study was however not directly related to the anti-resorptive 
bisphosphonate Zoledronate. The in vivo study in a rat model of postmenopausal osteoporosis showed an 
unexpected rapid mineralization of the nHA-loaded hydrogel already between day 3 and 10 after 
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implantation, with and without the presence of Zoledronate. The drug showed its strong effect from day 17 
and efficiently inhibited the resorption of present and newly formed bone as well as the degradation of the 
biomaterial. 
The cell proliferation assay that was performed with murine RAW 264.7 macrophages showed a dose-
dependent proliferation decrease for cells that were exposed to Zoledronate concentrations from 0.16 to 
40 µM. This inhibitory effect was significantly enhanced by the presence of hydroxyapatite nanoparticles 
that were added to the solution with a nHA/Zoledronate ratio of 10:1. Due to the high affinity of 
Zoledronate to hydroxyapatite, it must be assumed that most of the drug was absorbed to the particles and 
therefore not present in solution (Nancollas, Tang et al. 2006). Light microscopy images showed that the 
macrophages incorporated the Zoledronate-loaded particles surrounding them. This finding suggests that 
the cells have taken up the drug together with the nHA-particles. Thompson et al. have shown that 
aminobisphosphonates are typically internalized by macrophages and osteoclasts via fluid-phase 
endocytosis (pinocytosis) in vitro (Thompson, Rogers et al. 2006). Particles however have been shown to be 
incorporated by macrophages via pinocytosis only for sizes smaller 500 nm, larger particles are 
phagocytized (Kruth, Jones et al. 2005; Oh and Park 2014). The particles used for this study have a size of 
less than 200 nm but form agglomerations, so that both mechanisms have to be considered. A stronger 
inhibitory effect on macrophages has also been described for bisphosphonate-modified gold nanoparticles 
(size <100 nm) compared to unbound bisphosphonate (Fanord, Fairbairn et al. 2011). One possible 
explanation for this phenomenon given in this publication is that a greater concentration of drug molecules 
is introduced in cells with the particles as carrier. This can also be the case in the present study. An 
alternative explanation could be an enhancement of the bisphosphonate potency by the presence of 
calcium, phenomenon that has been demonstrated before (Thompson, Rogers et al. 2006). The Ca+ ions 
could originate from a dissolution of the hydroxyapatite in the macrophages (Bloebaum, Lundeen et al. 
1998). In order to rule out a negative effect of the nHA powder itself on the macrophages, we also cultured 
them only with particles. The results show that the cells tolerated well the presence of the particles. This 
finding is in accordance with literature as other studies have shown the HA-particles with different sizes 
and shapes do not considerably impact the viability of RAW 264.7 macrophages up to a concentration of 
500 µg/ml (Scheel, Weimans et al. 2009). 
Another cell culture experiment with RAW 264.7 macrophages was performed in the frame of this study to 
investigate the Zoledronate release from pure hydrogel compared to nHA-loaded hydrogel. This indirect 
assay, which can be considered as a functional assay, was sufficient to confirm the theory that the small 
Zoledronate molecules are released from the highly porous hydrogel with a burst release. The experiment 
also confirmed that the presence of the nHA completely changed the release profile. No drug was 
detectable in solution after 1 hour of incubation, which is supported by the finding of others that mineral-
bound bisphosphonates are only released spontaneously in an acidic environment as it can be found for 
example in the resorption pit of an osteoclast (Rogers, Gordon et al. 2000). 
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An unexpected original finding of this study was the rapid in vivo mineralization of the hydrogel that 
happened independently from the bisphosphonate in both groups. It is known that calcium phosphate 
particles can act as nucleation sites in hydrogel matrices that promote a HA precipitation (Gkioni, 
Leeuwenburgh et al. 2010). This phenomenon has been investigated mainly in vitro with simulated body 
fluids (Chen, Meng et al. 2011). But we could not find any publications showing such a rapid mineralization 
in vivo. Nejadnik et al. just recently published a study investigating the use of pure and bisphosphonate-
modified hyaluronic acid with calcium phosphate nanoparticles for bone repair (Nejadnik, Yang et al. 2014). 
Despite a mineral content of the gel in the same range (6 w/v% versus 10 w/v% in this study), they did not 
report a considerable mineralization of the hydrogels after 4 weeks of implantation in bony defects created 
in rat tibiae. However, newly formed bone was analyzed in their study only based on histology. Depending 
on the staining used, histology might not be the most appropriate technique to detect biomaterial 
mineralization. 
The highly mineralized spots that were found in the present study showed mainly a granule-like structure 
with a particle size of up to 50 µm which supports the theory that they were formed by hydroxyapatite 
deposition starting from the nHA-particles as nucleation points. In the nHA-Zol-Gel-group, the granules 
seemed to have fused even to larger mineralized regions as shown with histology. A complete integration 
of the newly formed granules into the bone matrix without any signs of inflammation or foreign body 
reaction confirmed their excellent biocompatibility and osteoconductivity. When comparing the nHA-Gel-
group of this study with the Gel-group of a former study that was treated with pure hydrogel (chapter 2), a 
significant difference in the early mineralization in the three outer analyzed layers (736-1472µm) was 
observed. The difference diminished over time and stayed only as a trend in the inner two layers. The 
explanation for this phenomenon is an initial rapid mineralization of the biomaterial followed by its 
simultaneously occurring degradation and penetration by bone tissue as shown by structural changes on 
the time-lapsed microCT scans and the terminal histology results. Large amounts of macrophages and giant 
foreign body cells could be found in the nHA-Gel-group, which shows an efficient biodegradation of the 
hydroxyapatite. Similar findings have been published by Arts et al. (Arts, Verdonschot et al. 2006) who have 
demonstrated that HA nano-powder is integrated in newly formed bone and efficiently recruits 
macrophages and osteoblasts in vivo.  
The obvious mineralization of the biomaterial complicated the evaluation of the drug effect on peri-implant 
bone. The in vivo microCT imaging does not allow a differentiation between newly formed woven bone and 
mineralized hydrogel. When comparing the mineralized tissue volume fraction and the mineralization rate 
of the nHA-Zol-Gel-group to the Zol-Gel-group of an earlier study (chapter 2) no significant differences can 
be detected at any time. However, there is a strong trend to more tissue mineralization in the two central 
layers of the analyzed region (368-736 µm) that appears early and remains during the whole study time. 
Contributors to this gain of mineralized tissue could be on one side the new woven bone formation and on 
the other side the biomaterial mineralization. In our earlier study, we stated that the discovered boost in 
early peri-implant bone formation was caused by an initial “flush” of all bone cells with bisphosphonate 
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(chapter 2). With the presented release study, we were able to show that this flush does not occur when 
nHA is included in the hydrogel matrix as the Zoledronate is absorbed to the particles. We did not 
investigate the release of particles from the gel as it is highly dependent on the shape, swelling state and 
surrounding tissue of the hydrogel and therefore difficult to mimic in vitro. However, it can be assumed 
that the release of the comparatively huge nHA-particles is significantly slower than the release of the small 
drug molecules. Orriss et al. showed in vitro that bisphosphonates bound to mineral are significantly less 
effective to osteoblasts compared to unbound bisphosphonate (Orriss, Key et al. 2009). As the non-
phagocytic osteoblasts are unlikely to incorporate Zoledronate-loaded particles, less influence on bone 
formation can be assumed for the nHA-Zol-Gel-group compared to the situation when Zoledronate is 
delivered from pure hydrogel. This theory is also supported by findings of Arslan et al. who could not find a 
significant influence of Alendronate soaked HA granules on bone formation compared to saline soaked HA 
in a OVX mandibular defect model (Arslan, Altundal et al. 2011) . Nevertheless, small, but still significant 
differences could be also shown for the mineralization rate between the nHA-Gel-group and the nHA-Zol-
Gel-group. From day 7 to 10 there was a higher mineralization rate seen in the nHA-Gel-group and from day 
31-58 in the nHA-Zol-Gel-group. The combination Zoledronate-nHA must then influence bone formation 
and/or biomaterial mineralization in a different way than pure nHA, the mechanism is however not clear. 
When looking at the demineralization rate, the strong inhibitory effect of Zoledronate becomes obvious in 
the highly significant differences between the nHA-Gel-group and the nHA-Zol-Gel-group. The microCT 
study and histology revealed that the drug did not only inhibit bone resorption but also biomaterial 
degradation as can be seen by the absence of macrophages and giant foreign body cells and much larger 
amounts of mineralized material remaining in the nHA-Zol-Gel-group. Histology also shows that the 
bone/biomaterial-construct in the nHA-Gel-group had already been remodeled to a trabecular structure 
whereas it is still rather compact in the nHA-Zol-Gel-group. Surprisingly, there is no difference in 
demineralization rate between the Zol-Gel-group from the former study and the nHA-Zol-Gel-group from 
the present study even very distant from the screw (1104-1472 µm) where the bone is very unlikely to be in 
contact with the hydrogel. Therefore there must be either a release of the drug-loaded particles or a 
release of the drug alone as it can be caused by the resorptive activity of osteoclasts or macrophages 
(Coxon, Thompson et al. 2006). The present study unfortunately could not give any answer to the question 
by which means and how far the drug-loaded particles move in the bone environment in vivo. 
MicroCT-based histomorphometry was chosen for the present study as we found it to be a very suitable 
technique for the long-term three-dimensional analysis of peri-implant bone remodeling (chapter 2). The 
unexpected rapid mineralization found in the present study however interfered with the bone analysis as 
the microCT scans do not allow a differentiation between bone and mineralizing biomaterial which is an 
inherent limitation of this study. This differentiation can only be done by means of histology which was 
scheduled for this study only at the end of the experimental period of 8 weeks. Future studies should 
therefore include more groups of animals so that histology can be already performed at earlier time points 
for an observation of synergies between bone formation and biomaterial mineralization. More experiments 
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are also needed for an understanding of the exact mineralization process and the composition and 
mechanical competence of the resulting mineral. The in vivo mineralization seems to be dependent on size, 
shape and material of the particles as well as on type, density and degradation profile of the hydrogel as 
similar studies with comparable materials did not report an in vivo mineralization (Nageeb, Nouh et al. 
2012; Martínez-Álvarez, González-Meli et al. 2013; Heo, Ko et al. 2014; Nejadnik, Yang et al. 2014). An 
investigation of the mechanical properties of the resulting material as it could be done by nano-indentation 
will be key when it comes to evaluate the stability of implants. 
The hydrogels containing pure or Zoledronate-loaded nHA-particles are both easy to apply to bone due to 
their soft consistency, which makes them ideal for an application to irregular shaped cavities like an implant 
bed or difficult to access bone defects. Both materials have also been shown to mineralize rapidly in vivo 
and to form a kind of osteoconductive mineral scaffold. This biodegradable scaffold is later on penetrated 
by bone cells and included in newly forming bone. But the indications for both materials still should not be 
the same. The nHA-loaded hydrogel induced some new bone formation within the biomaterial in the 
present study but was not able to stabilize the bone loss situation present in the OVX rats (chapter 2). 
Therefore a large amount of the material was already degraded during the experimental period and could 
not contribute to an improved implant fixation. The nHA-loaded hydrogel therefore could have more 
potential in the repair and sealing of bony defects in healthy bone. The hydrogel with nHA and Zoledronate 
however could be favorable for the repair of bone defects that require at the same time a preservation of 
the surrounding bone matrix. Attention has to be paid in this case to the drug dose and the density of the 
resulting mineralized spots. As the Zoledronate has a “protective” effect for the biomaterial and inhibits its 
degradation, there is a risk that the penetration by the bone tissue can become impossible if the 
biomaterial becomes too dense and cannot be resorbed. 
Despite the synergistic effects between hydroxyapatite nanoparticles and Zoledronate that we were able to 
show in vitro, it was not possible to answer the question if the use of a nHA-Zoledronate-hydrogel is further 
improving implant fixation compared to a hydrogel loaded only with Zoledronate. There was a non-
significant increase of the mineralized tissue volume fraction in an extended range around the implant, but 
large amounts of biomaterial residues with unknown mechanical properties require mechanical testing 
before drawing a final conclusion. For the moment we can only conclude that both tested materials seem 
to be good candidates for bone repair in different specific clinical situations. 
 Conclusion 3.6
The present study was able to show a synergistic effects between Zoledronate and nHA-particles in vitro as 
the inhibitory effect of the drug on macrophages was enhanced when administering Zoledronate absorbed 
on hydroxyapatite nanoparticles. Furthermore it could be demonstrated that nano-sized hydroxyapatite 
also can serve as nucleation points in hyaluronic acid hydrogel in vivo in a rat model of postmenopausal 
osteoporosis. The material is then rapidly mineralizing under formation of micrometer-sized granules. 
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Those highly mineralized spots have been shown to be highly biocompatible, biodegradable and to serve as 
scaffolds for new bone formation. The biomaterial mineralization also occurred when Zoledronate was 
absorbed to the nanoparticles before integrating them into the hydrogel. In this case, however, the forming 
granules were protected from degradation by the anti-resorptive effect of the bisphosphonate resulting in 
larger mineralized regions compared to drug free nHA-hydrogel. At the same time, Zoledronate was still 
released from the biomaterial and inhibited efficiently the resorption of peri-implant bone to a similar 
extent that pure hydrogel loaded with only the drug. It was however not possible to determine a synergistic 
effect of the nHA-Zoledronate combination on bone formation in vivo, as the microCT-based dynamic 
histomorphometry that was chosen to monitor the bone remodeling in vivo, did not allow a differentiation 
between bone formation and biomaterial mineralization. 
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 Abstract 4.1
A good fixation of osteosynthesis implants is crucial for a successful bone healing but often difficult to 
achieve in osteoporotic patients. One possible solution to this issue is the local delivery of bisphosphonates 
in direct proximity to the implants, a technique that has been shown to significantly improve implant 
anchorage. One critical aspect of this method, that has not yet been well investigated, is the time course of 
the implant fixation following the drug release. Usual destructive mechanical tests would have required 
large numbers of animals for this kind of investigation, therefore a micro-finite element (microFE) approach 
was chosen for the analysis of implant fixation in the present study. In vivo micro computed tomography 
(microCT) scans were performed first weekly and later bi-weekly after implantation of polymeric screws in 
the femoral condyles of 6 ovariectomized rats. In half of the animals, Zoledronate was released from a 
hydrogel matrix directly in the peri-implant bone stock, the other half of animals received only the screws 
and served as control. The time course of the implant fixation was investigated with linear elastic microFE 
models that were created based on the in vivo microCT scans. The numerical models were validated against 
experimental pullout-tests measurements in an additional cadaver study. The microFE analysis revealed a 
significant difference in force at yield between the Zoledronate treated group and the control group, which 
was 28% after 17 days of screw implantation, 42% after 31 days, and persisted until the end of the in vivo 
study at day 58 (p < 0.01). These results indicate the great potential of Zoledronate-loaded hydrogel for an 
enhancement of osteosynthesis implant fixation in impaired bone as they show that the implant anchorage 
improves fast and over a prolonged time. 
Keywords: Drug delivery; hydrogel; bisphosphonate; screw fixation, microCT, microFE 
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 Introduction 4.2
The success of orthopedic implants is highly depending on their anchorage in surrounding bone. A good 
implant fixation requires a good structural integration between bone and implant surface 
(osteointegration) as well as a strong bone structure around the implant that can resist the loads that are 
transferred from the implant to the bone (Schiuma, Plecko et al. 2013). Many successful strategies have 
been developed to improve the implant osteointegration such as surface topography changing treatments, 
osteoconductive coatings or surface functionalization with biological molecules (Jäger, Zilkens et al. 2007; 
Zhang, Myers et al. 2014). An improvement of the second aspect, the peri-implant bone quality, is however 
much more difficult to achieve. Due to the demographic changes in our population, more and more people 
suffer from age-related diseases impairing the bone structure such as osteoporosis (Hernlund, Svedbom et 
al. 2013). Affected patients have a significantly increased fracture risk and fracture treatment is challenging 
in their cases as osteosynthesis implants are difficult to anchor in the deteriorated bone structure 
(Cummings and Melton 2002; Broderick, Bruce-Brand et al. 2013). High complication rates, which are 
typical for osteoporotic fracture treatments, show the need for new strategies to enhance implant fixation 
in low quality bone. One of the most promising approaches that came up during the last years is the local 
delivery of anti-resorptive drugs such as bisphosphonates in the peri-implant bone. Several studies have 
shown that this strategy can locally enhance the bone density and therefore increase the mechanical 
stability of implants in animals and humans (Peter, Gauthier et al. 2006; Gao, Luo et al. 2009; Andersson, 
Agholme et al. 2010; Abtahi, Tengvall et al. 2012). The increase in implant fixation was measured in most of 
the published studies with terminal ex vivo mechanical tests such as pullout, pushout test or torque testing. 
As each destructive mechanical test requires the sacrifice of a group of animals, typically not more than 1 
or 2 time points were investigated (Skoglund, Holmertz et al. 2004; Peter, Gauthier et al. 2006; Andersson, 
Agholme et al. 2010; Qi, Hu et al. 2012). Consequently, only little is known about the time course of the 
bisphosphonate effect on implant fixation. The temporal effect, however, is a very important aspect 
regarding the fact that osteosynthesis implants are placed to stabilize bone fractures. A good fracture 
reposition and stabilization are crucial for a successful fracture healing (Augat, Simon et al. 2005). 
Therefore, the onset of the positive bisphosphonate effect on screw fixation should ideally occur as soon as 
possible after implantation and persist until the fracture has completely healed. This aspect has so far not 
been targeted by any of the published studies. 
One very promising approach to monitor implant fixation in vivo is a technique introduced by Wirth et al. 
that combines microCT imaging with a micro-finite element (microFE) analysis for the investigation of the 
stability of bone-implant constructs (Wirth, Mueller et al. 2010). This group demonstrated an excellent 
correlation between microFE predicted pullout strength and measured pullout strength in a cadaveric ovine 
vertebra model. Stadelmann et al. applied this technique for the first time to time-lapsed microCT scans 
from an in vivo rat model and obtained equally good correlations (Stadelmann, Conway et al. 2013). The 
use of in vivo microCT data for the microFE offers the unique possibility to closely monitor implant stability 
with a significantly reduced number of animals. In addition, important parameters affecting the implant 
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fixation can be identified easily as the mechanical information gained with the microFE can be directly 
linked with bone parameters measured on the microCT scans (Wirth, Goldhahn et al. 2011).  
The microFE analysis was used in the present study for the first time to investigate the temporal effect of a 
locally delivered bisphosphonate (Zoledronate in the present study) on the fixation of miniature screws in a 
rat femoral model of postmenopausal osteoporosis. The goal of this analysis was to determine if the local 
bisphosphonate delivery can achieve the fast and durable enhancement of implant fixation that is needed 
for osteosynthesis implants in osteoporotic bone.  
 Materials and Methods 4.3
The in vivo microCT data that provided the basis for the microFE models were obtained from an animal 
study published earlier by our group (chapter 2). Since the miniature polymer screws used in the in vivo 
study were not suitable for biomechanical pullout tests, we performed a complementary cadaver study 
with titanium screws on similar bone specimens and screw geometry but different screw material. This 
cadaver study provided the data to identify a suitable failure criterion for the microFE models.  
4.3.1 In vivo MicroCT Study 
The animal experiments were approved by the local animal care and use committee (license no. 2508.1, 
EXPANIM, SCAV, Epalinges, Switzerland). Briefly, in this study, eight ovariectomized rats were implanted 
with radiopaque polyetheretherketone screws in both femoral condyles. In the 4 animals of a first group 
(Zol-Gel-group), the pre-drilled screw holes (diameter 1.2 mm, depth 3.5 mm) were filled with 5 µl of a 
commercially available hyaluronic acid hydrogel (Termira AuxiGel™, Stockholm, Sweden) containing 1 
µg/ml of Zoledronate (Art.-Nr. ALX-430-153-0000, Enzo Life Sciences, Farmingdale, USA). The 4 rats of the 
second group (Control-group) received only screws. Both femurs of all animals were scanned with a special 
in vivo microCT for small rodents (Skyscan 1076, Bruker microCT, Kontich, Belgium) at day 3, 10, 17, 31, 45, 
and 58 after screw implantation. The used scanning parameters were published earlier (chapter 2). 
Hydroxyapatite-polymer phantoms with known bone mineral density served as references for the microCT 
calibration. Not all samples of this study could be used for the microFE study as some screw heads were 
broken. The final analyzed samples size in Zol-Gel-group was n = 6 for the first 4 measured time points, n = 
3 for the 5th time point and n = 4 for the last time point. The sample size in the Control-group was n = 6 for 
all time points, therefore a total of 67 microCT scans were analyzed. All animals were sacrificed at the time 
of the last microCT scan. 
4.3.2 Experimental Pullout Test 
Six adult female Sprague Dawley rat cadavers with a mean weight of 310 ± 30 g were retrieved from 
another animal study (license no. 2567.a), EXPANIM, SCAV, Epalinges, Switzerland). The rats were lactating 
for 7 days at the time of sacrifice and therefore presented a significantly reduced bone density compared to 
normal animals (Miller and Bowman 1998). The 12 femurs of the animals were dissected directly after 
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sacrifice and kept frozen in saline until use. After thawing, holes with a length of 3.2 mm were drilled 
unicortically in the femoral condyles with a motorized dentist’s drill (DEC 100, Nobelcare, Sweden). 
Custom-made aluminum screws (thread length 3 mm, diameter 1.4 mm) with a 20 mm long rod attached to 
them instead of a screw head were inserted manually in the pre-drilled holes (Figure 4.1, left). Aluminum 
was chosen as screw material because this material has sufficient mechanical competence for the 
mechanical testing, while being artifact-free in the microCT. The inappropriate biocompatibility of 
aluminum however makes its in vivo use impossible. 
The implanted specimens were wrapped in saline soaked gauze to keep them moist during the imaging and 
microCT scans were performed. The scanning parameters, adapted to the aluminum screws, were the 
following: spatial resolution 18.4 µm, 0.5 mm aluminum filter, voltage 60 kV, current 167 µA, exposure time 
480 ms, rotation step 0.4°, frame averaging 2.  
After the scanning, the specimens were positioned in acrylic glass rings (inner diameter 8 mm) with a 
guiding device that centered the screw in the ring before fixing them with dental cement (Technovit® 3040 
powder, Heraeus Kulzer, Hanau, Germany) (Figure 4.1, middle). This fixation technique was chosen in order 
to mimic the boundary conditions that were later used for the microFE study. 
 
Figure 4.1:   Preparation of the rat femurs for the  pullout test. Left: implantation of special aluminum screws in the femoral 
condyles. Middle: fixation of the specimen in acrylic glass rings with dental cement. Left:  pullout tests were performed with a 
tensile testing machine. 
The pullout test was performed with a tensile testing machine (ElectroPuls E3000, Instron, High Wycombe, 
England). The sample in the acrylic glass ring was placed under a plate with a 8 mm-hole that was fixed to 
the base of the machine. The rod as prolongation of the screw was passed through the hole and fixed in a 
special gripper that was attached to the head of the tensile testing machine (Figure 4.1, right). The head 
was moved up with a speed of 1 mm/min. Force and displacement were recorded with a frequency of 50 
Hz after a pre-load of 0.5 N was reached. Stiffness, force at yield, and force at pullout were determined for 
each sample from the resulting force-displacement curves. All calculations for this study have been done 
with Matlab (Mathworks, Natick, USA). 
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4.3.3 Image Processing 
The image processing process was identical for the in vivo study and the cadaver study, only the 
segmentation thresholds had to be adapted to the different screw materials and scanning parameters. The 
reconstruction of the projection images was done with NRecon and GPURecon Server (Bruker microCT) 
following a protocol that was published earlier (chapter 2). Image processing after reconstruction was done 
with CTan (Bruker microCT) and Amira® (FEI Visualization Sciences Group, Burlington, USA).  
The first step of the image processing was a reduction of the dataset size for an easier handling of the 
datasets. A VOI including the full diameter of the femur from 5 mm distal to 5 mm proximal to the screw 
was manually defined on all scans using CTan. The background and the patella were then removed with an 
automated algorithm. The pre-processed datasets were loaded in Amira® for a further processing with a 
custom written script. A 6 mm high reference dataset was created with the screw in the center and 
concentric regions measuring 3, 4, 5, 6, 7 and 8 mm in diameter around. All datasets were registered on the 
reference dataset, ensuring an equal alignment and positioning of all screws for the microFE analysis 
(Figure 4.2). In a next step, the datasets were transformed to the new position and resampled by a factor of 
3 using the standard interpolation mode of Amira®. The new voxel size after resampling was 55.2 µm. The 
reduction of the dataset size was necessary to make the image stacks compatible with Abaqus (Simulia, 
Velizy Villacoublay Cedex, France) for the microFE analysis, as this software can run only a limited number 
of elements. A noise reduction median filter was applied after transformation and resampling to smooth 
the resulting images. In a next step, the images were segmented by assigning different grey values to 
screw, background, bone, and bone marrow in each region allowing a separate analysis of bone and 
microFE results in different distances from the screw (Figure 4.2). The bone volume fraction (BV/TV) 
including both cortical and cancellous bone was analyzed in the inner region with a diameter of 3 mm on 
the processed microCT scans.  
 
Figure 4.2:   Image processing; processed microCT scan with centered screw and different grey values for concentric rings with 
diameters from 3 to 8 mm (A). bone within the 3 mm ring used for determining the bone volume fraction and the critical strain 
fraction (B) and full sample size with a diameter of 8 mm (C). MicroFE model of the pullout test (D): the sample was constraint in a 
ring with 8 mm diameter, the screw head was displaced vertically along the screw axis. 
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4.3.4 MicroFE Analysis 
Creation of MicroFE Models 
After image processing, linear elastic microFE models for all microCT scans from the in vivo and the cadaver 
study were created by converting image voxels to linear isotropic hexahedral finite elements (Muller and 
Ruegsegger 1995). A cube of the same size as a microCT stack was created in the commercially available 
simulation software Abaqus (Simulia). The cube was meshed with hexahedral elements whereas the edge 
length of one element in the model was equal to the edge length of one voxel in the pre-processed microCT 
datasets (55.2 µm). An in-house Matlab (Mathworks, Natick, USA) script was used to assign mechanical 
properties to the elements according on the grey values in the microCT datasets. Different properties were 
assigned to bone (E = 6.8 GPa, v = 0.3) (Stadelmann, Conway et al. 2013), bone marrow (E = 0.05 MPa, 
v = 0.3) (Perren 1979), the titanium screws of the in vivo study (E = 110 GPa, v = 0.32) and the aluminum 
screws of the cadaver study (E = 70 GPa, v = 0.35) (Stadelmann, Conway et al. 2013). No difference was 
made between the properties of cancellous and cortical bone as published before (Kabel, Van Rietbergen et 
al. 1999). Elements surrounding the bone, which were identified as background during image processing, 
were removed from the model. The nodes of bone elements located at the intersection with a virtual 8 mm 
ring around the screw were fully constrained according to the sample fixation during the experimental 
pullout test (Figure 4.2). A displacement of 0.1 mm along the screw axis was applied to the top surface of 
the screw head in order to simulate the pullout test. The microFE simulations were performed on a cluster 
(Castor, EPFL, Switzerland) consisting of 50 nodes with 16 CPUs and 64 GB user memory each. We analyzed 
the reaction force on the screw head associated to the displacement, the resulting bone stiffness and the 
corresponding octahedral shear strain (γoct) in the bone. Post-processing was done with an in-house python 
script.  
Identification of the Failure Criteria 
The failure criteria for the microFE models of the present study were identified based on the experimental 
results of the cadaver study. Therefore, the experimentally measured forces at yield and pullout were 
compared with the microFE predicted reaction force at different strain states. Bone failure was assumed to 
occur when a certain bone volume fraction within a predefined VOI exceeded a critical strain level. Instead 
of using an effective strain criterion as it has been done in other studies (Pistoia, Van Rietbergen et al. 
2002; Wirth, Mueller et al. 2010; Stadelmann, Conway et al. 2013), we have chosen an octahedral shear 
strain criterion as it has been shown to be a good predictor for the spatial distribution of micro-damage 
within trabecular bone (Nagaraja, Couse et al. 2005).  
For the determination of the best failure criteria for the forces at yield and pullout, we analyzed the 
microFE predicted reaction force at the points where a certain volume fraction of the bone within our pre-
defined ROI (highly strained bone volume fraction) passed a certain level of γoct. To identify the best linear 
correlation, we analyzed combinations of 3 VOIS (diameter 3 mm, 4 mm, and 5 mm, height constant at 6 
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mm), 3 levels of γoct (0.5, 0.7, 1.0%) and 6 highly strained bone volume fractions (from 5 to 30 %). The 
analyzed strain range was chosen based on values found in the literature (Carter, Caler et al. 1981; Morgan 
2009). The combination that provided the highest coefficient of determination (R2) and the lowest p-value 
was chosen as critical strain level and critical highly strained bone volume fraction for a prediction of the 
force at yield and at pullout in the in vivo study. 
The experimentally measured stiffness from the cadaver study was compared to the microFE predicted 
stiffness to test for a linear correlation and to determine a scaling factor as microFE is known to significantly 
overestimate the bone-implant stiffness (Wirth, Mueller et al. 2010). 
Analysis of the In vivo Data 
After identification of the failure criteria and the correlations, the microFE models created from in vivo 
microCT scans were used to predict the force at yield and pullout as well as the bone-implant stiffness for 
all specimens at the 6 analyzed time points. Furthermore, all possible correlations between BV/TV, 
stiffness, force at yield and force at pullout were examined for both the cadaver and the in vivo study. 
Finally, BV/TV from the cadaveric study was compared with the initial BV/TV of the in vivo Control-group to 
test the comparability between the results. 
4.3.5 Statistical Analysis 
The statistics analysis was done with Matlab. Significant differences between the two groups were assumed 
for a p-value smaller than 0.05 and tested with a Wilcoxon rank sum test as not all results were normally 
distributed.  
 Results 4.4
4.4.1 Experimental Pullout Test 
Nine specimens were analyzed in total, 3 had to be excluded due to an atypical force-displacement curve 
without detectable yield that suggested that the screws were loose already at the beginning of the test. 
The average force at yield was 15.4 ± 2.4 N (from 11.1 N to 20.1 N), the average force at pullout was 
21.6 ± 4.0 N (from 13.0 N to 29.5 N), and the average bone-implant stiffness was 107.6 ± 25.7 N/mm (from 
59.2 N/mm to 150.1 N/mm). A close inspection of the screws after pullout did not show any damage to the 
screw threads. 
4.4.2 Identification of the Failure Criteria for the MicroFE Models 
Nine microFE models were created, one for each experimentally analyzed cadaveric femur. All of them run 
successfully. The meshing took in average 4 min, the resulting number of elements ranged between 
680’000 and 980’000. The degrees of freedom in the models ranged from 2.1 to 3.1 million, the simulation 
time needed was around 6 hours for each sample. The coefficients of determination (R2) and p-values of all 
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analyzed combinations of VOI, highly strained bone volume fraction and γoct can be found in Table 4.1 for 
the force at yield and in Table 4.2 for the force at pullout. 
Force at yield Highly strained bone volume fraction 
 
γoct 
level 
5% 10% 15% 20% 25% 30% 
R2 p R2 p R2 p R2 p R2 p R2 p 
VOI 
Ø 3 mm 
0.5% 0.576 0.0178 0.574 0.0181 0.594  0.643 0.0151 0.726 0.0036 0.751 0.0025 
0.7% 0.567 0.0192 0.576 0.0178 0.597  0.645 0.0147 0.733 0.0032 - - 
1% 0.571 0.0184 0.580 0.0172 - - - - - - - - 
VOI 
Ø 4 mm 
0.5% 0.541 0.0238 0.540 0.0241 0.561  0.590 0.0156 0.583 0.0166 - - 
0.7% 0.539 0.0244 0.541 0.0238 0.561  - - - - - - 
1% 0.541 0.0239 0.544 0.0233 - - - - - - - - 
VOI 
Ø 5 mm 
0.5% 0.430 0.0222 0.563 0.0199 0.573  0.548 0.0226 - - - - 
0.7% 0.553 0.0217 0.563 0.0199 0.575  - - - - - - 
1% 0.556 0.0211 - - - - - - - - - - 
Table 4.1:   Coefficients of determination (R
2
) and p-values for the linear correlation between the measured and predicted force at 
yield for different octahedral shear strain levels and different highly strained bone volume fractions measured in 3 VOIs. Empty 
cells mark combinations where the strain levels were not reached in the specified bone volume fraction (italic values: p<0.01). 
Force at pullout Highly strained bone volume fraction 
 
γoct 
level 
5% 10% 15% 20% 25% 30% 
R2 p R2 p R2 p R2 p R2 p R2 p 
VOI 
Ø 3 mm 
0.5% 0.423 0.0580 0.423 0.0580 0.448 0.0487  0.502 0.0326  0.592 0.0154  0.651 0.0086  
0.7% 0.413 0.0622 0.425 0.0572 0.450 0.0480  0.505 0.0320  0.605 0.0136  - - 
1% 0.417 0.0601 0.427 0.0561 - - - - - - - - 
VOI 
Ø 4 mm 
0.5% 0.409 0.0636 0.416 0.0609 0.448 0.0485  0.500 0.0332  0.526 0.0270  - - 
0.7% 0.405 0.0654 0.417 0.0603 0.449 0.0482  - - - - - - 
1% 0.406 0.0647 0.419 0.0594 - - - - - - - - 
VOI 
Ø 5 mm 
0.5% 0.430 0.0553 0.459 0.0450  0.501 0.0337  0.507 0.0315  - - - - 
0.7% 0.433 0.0540 0.458 0.0451  0.501 0.0328  - - - - - - 
1% 0.436 0.0528 - - - - - - - - - - 
Table 4.2:   Coefficients of determination (R
2
) and p-values for the linear correlation between the measured and predicted force at 
pullout for different octahedral shear strain levels and different highly strained bone volume fractions measured in 3 volumes of 
interest. Empty cells mark combinations where the strain levels were not reached in the specified bone volume fractions (italic 
values: p<0.01). 
For both force at pullout and force at yield, the best correlations between numerical predictions and 
experimental measurements were obtained for a highly strained bone volume fraction of 30% at an 
octahedral shear strain level of 0.5% measured within a cylindrical VOI with a diameter of 3 mm. This 
finding is in agreement with a linear correlation between experimental force at yield and experimental 
force at pullout (R2 = 0.887, p = 0.0002). The correlation between measured and predicted force at yield 
was better (R2=0.751 / p=0.0025) than between measured and predicted force at pullout (R2=0.651 / 
p=0.0086). Both predicted forces were overestimated by the numerical model by a factor of 6.4 and 10.5. 
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Therefore, the predicted forces for the in vivo study were corrected based on the identified correlations 
(Figure 4.3). 
 
Figure 4.3:   Correlation between measured and predicted force at yield (left) and measured and predicted force at pullout (right); 
the experimental and numerical results were obtained from the rat cadaver study. 
A significant but weaker linear correlation was obtained for the measured and predicted bone-implant 
stiffness (R2 = 0.524, p = 0.0275) (Figure 4.4). The predicted stiffness was highly overestimated by a factor 
of 32.7 and again corrected based on the correlation for the in vivo study.  
 
Figure 4.4:   Correlation between measured and predicted bone-implant stiffness; the experimental and numerical results were 
obtained from the rat cadaver study. 
4.4.3 Analysis of the In vivo Study 
All 67 microFE models were created and analyzed successfully. Values for the force at yield and force at 
pullout as well as for the bone-implant stiffness were predicted for all samples at all analyzed time points 
(Figure 4.5).  
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Figure 4.5:   One sample from each group showing the octahedral shear strain maps and corrected reaction forces at each time 
point determined for a screw head displacement of 0.03 mm 
The initial predicted force at yield was 16.4±1.1 N in the Control-group and 16.1±1.0 N in the Zol-Gel-group 
(Figure 4.6 left). In the Control-group, it increased by 9% to 17.8±1.3 N between day 3 and day 10 and then 
did not show any marked changes until day 58. For the Zol-Gel-group, however, a total increase in the 
predicted force at yield of 50% to 24.1±1.4 N was found between day 3 and day 31 followed by a slight 
decrease by 4% until day 58. The difference between the two groups was highly statistically significant 
starting from day 17. A similar time course was also found for the force at pullout (Figure 4.6 right) and the 
predicted stiffness (Figure 4.7) due to the correlations between all parameters. The force at pullout 
increased in the Control-group from 23.4±1.7 N at day 3 by 10% to a maximum of 25.8±2.2 N at day 10 and 
did not change significantly any more until the end of the study. The Zol-Gel-group started with a force at 
pullout of 23.0±1.6 N that increased in total by 57% up to 36.0±0.8 at day 31 followed by slight decrease of 
3% until day 58. The initial value of the predicted stiffness was 145.5±12.7 N/mm in the Control-group and 
147.3±17.8 N/mm in the Zol-Gel-group and rose by 16% to 169.9±23.0 N/mm at day 58 in the Control-
group and by 55% to 229.1 N/mm at day 45 in the Zol-Gel-group. Again, a statistically significant difference 
was found between the groups starting from day 17. 
 
Figure 4.6:   Time course of the predicted force at yield (left) and force at pullout (right) for the two groups of the in vivo study. The 
values were corrected based on the correlations identified in the cadaver study. 
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Figure 4.7:   Time course of the predicted stiffness for the two groups of the in vivo study. The values were corrected based on the 
correlations identified in the cadaver study. 
The test for linear correlation of all measured parameters of the cadaver study revealed a strong linear 
correlation between force at yield and force at pullout (R2=0.886), weak correlations between BV/TV and 
force at yield (R2=0.468), BV/TV and stiffness (R2=0.480), and force at yield and stiffness (R2=0.583). No 
correlation was found for the other combinations (Table 4.3). For the measured BV/TV and all predicted 
parameters of the in vivo study, we found high linear correlations between BV/TV and force at yield/pullout 
(R2=0.822) and stiffness and force at yield/pullout (R2=0.862) and a lower correlation for BV/TV and 
stiffness (R2=0.671) (Table 4.3). As force at yield and force at pullout are determined based on the same 
reaction force from the model, their correlation is one and they have equal R2 when compared with other 
parameters. The very low p-values found for the correlations of the in vivo study are caused by the high 
number of samples (n=67). 
 Cadaver study (n=9) In vivo study (n=67) 
- Linear correlation with - R2 p R2 p 
BV/TV Force at yield 0.468 0.042 0.822 0.0000 
BV/TV Force at pullout 0.349 0.0942 0.822 0.0000 
BV/TV Stiffness 0.480 0.0386 0.671 0.0000 
Stiffness Force at yield 0.583 0.0166 0.862 0.0000 
Stiffness Force at pullout 0.378 0.0781 0.862 0.0000 
Force at yield Force at pullout 0.886 0.0002 1 0.0000 
Table 4.3:   Coefficients of determination (R
2
) and p-values for the linear correlations between all measured parameters of the 
cadaver study and the measured BV/TV and all predicted parameters of the in vivo study (underlined values: p<0.05, italic values: 
p<0.01). 
 Discussion 4.5
The goal of the present study was to investigate the temporal influence of locally delivered Zoledronate on 
the implant fixation in a rat model of postmenopausal osteoporosis. This was done based on time-lapsed in 
vivo microCT scans that were taken weekly to bi-weekly from the screw implantation sites. The scans were 
used to create linear elastic microFE models that could predict force at yield and pullout as well as stiffness 
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of the bone-implant construct. With this microFE approach, we were able to confirm for the first time 
numerically the positive effect of locally delivered Zoledronate on implant fixation. More importantly, the 
combination of in vivo microCT with microFE analysis revealed insights in the time course of the 
Zoledronate effect showing that a significant enhancement of screw fixation can be expected in rats as 
early as 17 days after implantation and can persist for minimum 6 weeks after onset. This result is of great 
importance considering the aim of the local bisphosphonate delivery, which is the rapid stabilization of 
osteosynthesis implants in osteoporotic patients. The possibility for an early loading of the implant is crucial 
for a mobilization of the patients. Therefore, the drug effect should occur as soon as possible after 
implantation and persist until the fracture has healed completely.  
A close investigation of the results from this study highlighted that the load in this femoral model of 
postmenopausal osteoporosis is mainly transmitted from the screw in the cortical bone as only little 
amounts of cancellous bone structure are left over. The increase in force at yield and pullout as well as the 
stiffness in the Zol-Gel-groups is also caused to a high extent by the periosteal callus formation and 
resulting thickening of the cortex, which was observed in this group around the screw head (chapter 2). The 
newly formed trabecular bone seems to play a less significant role for the load transfer. No significant callus 
formation was observed in the control group, which explains the small increase in predicted force at yield, 
by only 9% that occurred already during the first 10 days. Stadelmann et al. investigated the time course of 
the implant fixation in rat tibia without any pharmacological treatment (Stadelmann, Conway et al. 2013). 
They reported a time course similar to the one found in the present study for the force at yield with a peak 
at day 9, the reported maximum gain in force at yield however was much higher with 71% (Stadelmann, 
Conway et al. 2013). This significant difference might have been caused by the difference in screw size and 
geometry as well as by the intact trabecular bone structure of the healthy rats used in their study. The 
values for force at yield and pullout as well as for the stiffness reported in the present study are in general 
low compared to published data from other rat studies (Andersson, Agholme et al. 2010; Stadelmann, 
Conway et al. 2013). This can be explained by the experimental pullout test conditions of the present study 
including small screw size, the non-osteointegrated state of the screws and the low bone density of the rat 
cadavers used. When comparing the results obtained in this study with previously published experimental 
data, excellent accordance can be found. Skoglund et al. performed pullout tests with miniature screws 
implanted in rat tibiae. They reported a 15% larger force at pullout and 28% higher stiffness in animals that 
received miniature screws with a local dose of Ibandronate compared to control 14 days after implantation 
(Skoglund, Holmertz et al. 2004). We found an increase in predicted force at pullout of 8% after 10 days and 
32% after 17 days as well as an increase in stiffness of 16% after 10 days and 35% after 17 days for the 
Zoledronate treated animals. Other studies obtained also similar values two weeks after screw 
implantation and bisphosphonate release (Tengvall, Skoglund et al. 2004; Wermelin, Aspenberg et al. 
2008). One more study from the Aspenberg group reported a 41% increase in pullout force for 
bisphosphonate coated screws after 4 weeks (Agholme, Andersson et al. 2011) which corresponds again 
very well with the 42% increase that we found after the same time period. We found only one long term 
study published by Wermelin et al. that investigated the temporal effect of Pamidronate and Ibandronate 
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immobilized on stainless steel screws via a fibrinogen layer on screw fixation (Wermelin, Tengvall et al. 
2007). For screws that were implanted close to the diaphyseal area in rat tibiae, a position comparable in 
terms of trabecular bone density to our OVX femoral model, they reported an increasing difference in 
pullout load between control and bisphosphonate animals until week 4 (69%) which diminished at week 8 
(43%). In the present study the peak difference between Control-group and Zol-Gel group was also 
identified at week 4 (42%) and slightly diminished at week 6 (39%) and week 8 (31.5%). Lower values in the 
present study might again be caused by smaller screws and the reduce trabecular bone density. 
The screws used in the present in vivo study were made from a special barium sulfate-loaded PEEK that is 
visible on microCT scans but, unlike titanium or stainless steel implants, does not cause artifacts. This way 
we eliminated one of the limitations of other microFE studies which were based on in vivo microCT 
presenting metal artifact biased peri-implant bone structure (Wirth, Mueller et al. 2010; Stadelmann, 
Conway et al. 2013). At the same time, the comparatively soft polymer screws did not allow us performing 
pullout tests for a validation of the model. Therefore, we did a complementary study with rat cadavers for 
an identification of the possible correlations, which was designed to be as similar as possible to the actual 
in vivo study. The aluminum screws used for the cadaver study had an identical geometry than the PEEK 
screws of the in vivo study. Aluminum was chosen as screw material, as it is artifact-free in the microCT and 
has at the same time sufficient mechanical properties for a pullout test. The bone loss situation was 
comparable in the lactating rats of the cadaver study and the OVX rats of the in vivo study as confirmed by 
comparison of the BV/TV. In the cadaver study we found a good linear correlation between predicted and 
measured force at yield (R2 = 0.75 / p=0.003) and a weaker correlation for the force at pullout (R2 = 0.65 / 
p=0.009) within a VOI of 3 mm diameter, with an octahedral shear strain level of 0.5% and a highly strained 
bone volume fraction of 30%. A significant but weaker linear correlation was also found for the measured 
and predicted stiffness (R2 = 0.52 / p=0.03). Wirth et al. and Stadelmann et al. also reported a good 
correlation for the failure load but did not find any correlation between predicted and measured stiffness in 
cadaver or ex vivo studies (Wirth, Mueller et al. 2010; Stadelmann, Conway et al. 2013). One possible 
explanation for this difference is probably due to our osteoporotic model with a load transfer from the 
comparatively small screws mainly into the cortices.  
The numerical models used for the present study were purely linear elastic, therefore only the linear elastic 
first part of the pullout test could be reliably predicted. The weak linear correlation that was found in this 
study between the measured and predicted force at pullout is caused by a linear correlation between the 
measured force at yield and the measured force at pullout. This linear correlation is not typical for pullout 
tests with bone screws (Stadelmann, Conway et al. 2013) and must be considered as being model-specific. 
Another limitation concerns the interface between screw and bone, which was considered as being rigid in 
the numerical models. This assumption might be justifiable for fully osteointegrated screws but is 
questionable for screws directly after insertion or implanted into cadaveric bone. However, in screws unlike 
in pins, the threaded part of the screw achieves a form closure and prevents friction to have a decisive 
contribution to the pullout forces (Wirth, Mueller et al. 2010; Stadelmann, Conway et al. 2013).  
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A down sampling of the element size from 18.4 µm (microCT resolution) to 55.2 µm was necessary to 
reduce computational costs, but it might have also distorted thin trabecular structures (Cooper, Turinsky et 
al. 2007). However, as mentioned above, the main loads in this osteoporotic model are taken by the 
cortices. Those are comparatively wider and therefore less sensitive to the bias that is caused by a 
reduction of the resolution. One further limitation that affects microCT based studies in general is the fact 
that computed tomography can detect the degree of mineralization of the bone but is unable to 
differentiate between mature lamellar bone and unstructured woven bone (Mulder, Koolstra et al. 2008). 
Woven bone can have a higher degree of mineralization than lamellar bone, but its irregular oriented 
collagen fibers and irregular mineralization patterns make it mechanically inferior (Currey 1998). The 
microFE approach considers all bone parts that exceed a certain mineralization degree (grey value 
threshold for bone segmentation) as equally mechanical competent. This might be a disadvantage in the 
current study as the bone trauma caused by the insertion of an implant is known to cause a rapid formation 
of woven bone in direct proximity of the implant (Marco, Milena et al. 2005). We recently showed that this 
early peri-implant bone formation is even enhanced by a fast local delivery of Zoledronate (chapter 2). 
Studies have also shown that the bisphosphonate can delay the remodeling of the newly formed woven 
bone to lamellar bone (McDonald, Dulai et al. 2008), however the intrinsic mechanical properties of healing 
bone should not be affected by the bisphosphonate (Amanat, He et al. 2008). All those processes and 
factors are not taken into account in the microFE analysis. For future studies, one possible improvement for 
this limitation could be the combination of dynamic histomorphometry and microFE (Schulte, Lambers et 
al. 2011) (chapter 2) to identify newly formed bone. Depending on the maturity of the bone, the bone 
properties could then be adapted in the microFE model.  
Despite several inherent limitations, the good correlations between the results of the present study and 
published experimental and numerical data confirm the great potential of microFE analysis to predict the 
time course of implant fixation in vivo and how it is altered by the presence of the locally delivered 
Zoledronate. 
 Conclusion 4.6
With the present study, we were able to show the time course of the Zoledronate effect on implant fixation 
in vivo based on microFE analysis. The locally delivered bisphosphonate was predicted by the microFE 
model to significantly improve force at yield and pullout as well as stiffness already 2 weeks after screw 
implantation in a femoral rat model of postmenopausal osteoporosis. The difference between the groups 
persisted until the end of the study after 8 weeks. Those results indicate that the local delivery of 
bisphosphonates from a hydrogel matrix can improve the fixation of implants in impaired bone rapidly and 
over a long time. These are very important aspects considering the fact that the bisphosphonate delivery 
system is intended to stabilize osteosynthesis implant systems in osteoporotic bone. 
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 Discussion and Perspectives Chapter 5
 Clinical Situation and Specifications for the Drug Delivery System 5.1
Osteoporosis is one of the major health problems in our aging population. This metabolic bone disease, 
characterized by a reduced bone mass and a deteriorated bone microstructure, affected 27.5 million 
individuals in the European Union in 2010, this number is expected to rise by 23% to 2025 (Hernlund, 
Svedbom et al. 2013). The main clinical consequences of osteoporosis are fragility fractures that are 
associated with severe pain and suffering, disability and even death for the patients and a substantial 
economic burden for the society. The costs caused by osteoporosis were estimated to € 37 billion in 2010 in 
the European Union, whereas 66% were spent for incident fractures and 29% for long term fracture care 
(Hernlund, Svedbom et al. 2013). The main challenge for the treatment of osteoporotic fractures is a 
reliable anchorage of osteosynthesis implants in the impaired bone (Cornell 2003; Broderick, Bruce-Brand 
et al. 2013). A stable internal or external fixation, however, is crucial for a rapid bone healing, return of 
function and the prevention of complications (Lampropoulou-Adamidou, Karampinas et al. 2014). 
Therefore many new strategies to improve implant fixation have been developed and tested during the last 
decade, including mechanical and pharmaceutical approaches (Pioletti, Gauthier et al. 2008; Aspenberg 
2009; Augat and Buhren 2010; Kammerlander, Erhart et al. 2013). The demands on new techniques and 
devices are high. In order to reduce the morbidity of the mainly elderly osteoporotic patients, their 
mobilization after fracture treatment has to occur as soon as possible (Beaupre, Binder et al. 2013; Liem, 
Kammerlander et al. 2013). Consequently, the fixation of osteosynthesis implants in the distorted 
osteoporotic bone has to be optimally strong and reliable from the time of implantation until the end of the 
bone healing process. At the same time, the device should ideally have no negative long-term effects on 
the bone and should not interfere with revision surgeries or implant removal. Until now, no technique was 
found that could meet all those requirements. New implant designs and mechanical fixation concepts like 
locking plates have shown to improve the load transmission and distribution in deteriorated bone 
(Kammerlander, Erhart et al. 2013; Lampropoulou-Adamidou, Karampinas et al. 2014). However, the 
insufficient bone strength remains an unsolved underlying problem of the difficult implant fixation; 
therefore, the success of this approach is limited. Another strategy is the augmentation of implants, in this 
case mostly bone screws, with PMMA or calcium phosphate bone cements (Amendola, Gasbarrini et al. 
2011; Larsson, Stadelmann et al. 2012; Namdari, Rabinovich et al. 2013). This approach has been shown to 
enhance significantly the primary stability of implants (Fensky, Nüchtern et al. 2013; Gradl, Knobe et al. 
2013). But as those cements are either non-degradable (PMMA) or only slowly degradable (calcium 
phosphate), they can be dangerous when leaking into fracture sites or surrounding organs and soft tissues 
(Sermon, Hofmann-Fliri et al. 2014) and they might impair the surrounding bone on the long term (Huang, 
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Yan et al. 2005; Lindner, Kanakaris et al. 2009). The most promising pharmaceutical approach investigated 
during the last years is the local delivery of anabolic or anti-catabolic drugs to the peri-implant bone. Most 
of the published studies addressed the release of the anti-resorptive bisphosphonates (BPs) and could 
show positive effects on peri-implant bone density and implant fixation in animal models and humans 
(Peter, Gauthier et al. 2006; Abtahi, Tengvall et al. 2012; Bobyn, Thompson et al. 2014). Anabolic 
substances like strontium ranelate or growth factors have been tested as well but shown to be less efficient 
in improving implant fixation (Andersen, Offermanns et al. 2013; Fu, Zhang et al. 2014; Ross, Hamilton et al. 
2014). Drug delivery systems can significantly enhance the osteointegration and peri-implant bone density 
in the longer term but all of them failed so far to improve the primary stability of the implants. Attempts 
have been made recently to optimize the results by combining different approaches for example by loading 
bone cements with BPs (Sörensen, Arnoldi et al. 2013), but the perfect solution still could not been found. 
 Hydrogel as Drug Delivery System for Bisphosphonates 5.2
The main goal of the present doctoral thesis was the development of a BP delivering hydrogel targeting the 
improvement of implant fixation in osteoporotic bone. The studies performed in the frame of this thesis 
revealed that hyaluronic acid hydrogels are suitable drug delivery systems for BPs that show inherent 
advantages over other known release systems. The first positive aspect of using a hydrogel as drug delivery 
system is the simplicity of the application. The mechanical properties of the hyaluronic acid hydrogel can be 
tailored to specific implantation sites by selecting appropriate polymer concentrations or molecule sizes as 
well as by crosslinking processes (Holloway, Ma et al. 2014). The gel can be applied to the prepared implant 
bed by simple injection, as a pre-shaped bulk material or even in lyophilized dry form. At the same time, 
the viscosity of the hydrogel keeps the drug from being washed away, as would occur when applying a 
simple drug solution. We could show in this thesis that the gel is pushed in the bone cavities during implant 
insertion. This way, even bone further away from the implant comes in direct contact with the drug.  
This seems to be an important aspect as BPs have a high affinity to bone mineral and therefore stay highly 
localized when released into bone (Nancollas, Tang et al. 2006; McKenzie, Dennis Bobyn et al. 2011). The 
animal studies of this thesis revealed the strongest drug effect on bone formation and resorption within the 
bone region where a direct contact between Zoledronate-loaded hydrogel and trabecular bone was 
assumed (0-750 µm from the screw surface) (chapter 2). A weaker effect, however, was also seen in the 
region between 750-1500 µm from the surface suggesting that there was nevertheless some diffusion of 
the drug. Earlier studies of our group performed with Zoledronate absorbed to hydroxyapatite coated 
titanium implants showed with similar drug doses only very localized effects within a range of 70-250 µm 
from the implant surface in rats and 400 µm from the implant surface in sheep (Peter, Pioletti et al. 2005; 
Peter, Gauthier et al. 2006; Stadelmann, Gauthier et al. 2008). Those results confirm also the findings of 
other publications stating that BPs are not easily released from mineral surfaces as a release requires 
certain conditions such as an acidic environment (Ebetino, Francis et al. 1998). In addition, once the BP 
molecule is dissociated from the bone, long diffusion paths are inhibited by a fast re-absorption (Russell, 
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Watts et al. 2008). Taken together, the results of this thesis clearly suggest that the penetration of the bone 
with a BP-loaded matrix has the advantage of a significantly enlarged range of action compared to a 
delivery from the implant surface as it is achieved with a drug releasing coating.  
Another positive aspect of the BP release via a hydrogel seems to be the fast release of the small drug 
molecules from the highly porous polymeric matrix. We were able to confirm this burst release with an 
indirect cell assay demonstrating that around 75% of the drug are released from a hyaluronic acid hydrogel 
within one hour of incubation in water (chapter 3). We stated that this initial “Zoledronate flush” of the 
peri-implant bone might be responsible for the positive effect on early bone formation that we 
demonstrated in vivo (chapter 2). Numerous in vitro studies have shown that BPs can have positive or 
negative effects on osteoblasts, depending on the drug dose and study design (Pan, To et al. 2004; Greiner, 
Kadow-Romacker et al. 2006; Idris, Rojas et al. 2008; Orriss, Key et al. 2009). The in vitro cell assay results, 
however, are very difficult to use for a prediction of the in vivo situation as the fast absorption of BPs to 
bone prevents osteoblasts from being exposed to high drug concentrations in solution, as it is the case in 
cell culture assays. Unlike osteoclasts, osteoblasts do not have the ability to liberate BPs from the bone 
surface (Rogers, Gordon et al. 2000; Coxon, Thompson et al. 2008). A burst release of the BP in direct 
proximity to the osteogenic cells, however, might be sufficient to stimulate other cell types than osteoclasts 
and macrophages.  
The superiority of a burst release of BPs release to a slow controlled release is also suggested by the results 
of a rat fracture healing study performed by McDonald et al. (McDonald, Dulai et al. 2008). The group 
demonstrated that a systemic bolus administration of Zoledronate increased callus size and strength while 
allowing hard callus remodeling only with a short delay compared to control. A distribution of the same 
Zoledronate dose over a period of 5 weeks, however, significantly affected the remodeling long after 
cessation of the treatment. This is also important information considering the fact that the Zoledronate-
loaded hydrogel is intended to be used to stabilize osteosynthesis implants in proximity to a fracture site, 
therefore a drug effect on the fracture healing cannot be excluded. The positive effect of BPs on early callus 
size and strength described by McDonald et al. and other studies (Fleisch 2001; Amanat, Brown et al. 2005; 
McDonald, Dulai et al. 2008; Matos, Tannuri et al. 2010) is desirable. An inhibition of the hard callus 
remodeling as it has been associated with a prolonged BP administration, nevertheless has to be avoided. 
To sum up, there is much to suggest that hydrogels and in particular the biodegradable hyaluronic acid are 
favorable biomaterials for a local release of bisphosphonates in peri-implant bone presenting many 
advantages over other systems such as slow releasing coatings.  
 Applicability of the New Drug Delivery System 5.3
The ideal application areas for pure hydrogel containing only the BP are bone regions with insufficient bone 
density and bone strength, where the formation of new bone needs to be encouraged while avoiding a 
resorption of the existing bone stock. This is typically the case in the surrounding of osteosynthesis 
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implants such as bone screws especially if those have to be anchored in the trabecular bone of the 
epiphyseal and metaphyseal regions of long bones. Implant placement in these sites is known to be 
particularly difficult in osteoporotic patients (Stromsoe 2004). The microFE study that was performed for 
this thesis nevertheless revealed that the gain in stiffness and force at pullout in Zoledronate treated OVX 
rats was caused to a high extent by a periosteal callus formation around the screw with resulting thickening 
of the cortex (chapter 4). This result suggests that an application of the BP-loaded hydrogel could also be 
favorable in the diaphyseal regions of long bones.  
Another possible application for the BP-hydrogel could be the bone stock around joint replacing 
endoprostheses. Hilding et al. demonstrated that locally applied Ibandronate significantly reduced the 
migration of cemented total knee prostheses in humans (Hilding and Aspenberg 2007). A meta-analysis of 
14 randomized trials revealed that systemically administered BPs could also significantly inhibit peri-
implant bone loss up to 72 months after joint replacement surgery without reporting any serious side 
effects related to the drug (Lin, Yan et al. 2012). Those promising findings encourage a further investigation 
of the use of BP-hydrogels for an enhanced osteointegration of long-term implants such as endoprostheses 
while preventing peri-implant bone loss.  
In the frame of this thesis, we also tested the hyaluronic acid hydrogel in combination with Zoledronate-
loaded hydroxyapatite nano-particles (nHA) in our rat model. Prior cell culture assays had shown an 
enhancement of the inhibitory effect on murine macrophages by the presence of the hydroxyapatite 
particles (chapter 3). In vivo we had the much-unexpected effect of a rapid mineralization of the hydrogel 
due to the presence of the nHA. The mineralized and therefore microCT-detectable hydrogel inhibited an 
investigation of the precise bone formation and resorption processes as bone and mineralized material 
could not be distinguished on the microCT scans. Histology performed at the end of the study showed in 
both experimental groups, receiving either nHA-hydrogel and or nHA-hydrogel with Zoledronate, the 
formation of mineralized granules that served as scaffold for new bone formation. In the animals that had 
the nHA loaded with Zoledronate, we detected a complementary anti-resorptive effect on both the 
mineralized hydrogel and the surrounding bone. The finding that the hydrogel might serve as in situ 
forming scaffold requires a closer investigation but it might extend the area of application for the particle-
loaded hydrogel to non-load-bearing, difficult-to-access bone defects. The hydrogel loaded only with the 
HA-particles could be used in patients with normal bone quality to fill bone defects that appear for example 
after implant or bone tumor removal to encourage new bone formation without leaving bulky residues as 
can be seen after the use of bone cements. A loading of the HA-particles with a BP might be very useful for 
cases where bone loss is a concern, for example in osteoporotic patients or for the gap filling around 
implants where peri-implant bone loss is expected. 
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 Perspectives 5.4
5.4.1 Testing the Model and Dose Dependency of the Results 
The in vivo studies performed as part of this thesis used only one drug dose of 5 µg per implant. This dose 
was based on similar studies that reported a positive effect on peri-implant bone for locally applied 
Zoledronate doses from less than 1 µg to 20 µg (Peter, Gauthier et al. 2006; Greiner, Wildemann et al. 
2008; Andersson, Agholme et al. 2010). We were the first to show with a microCT based dynamic bone 
monitoring that Zoledronate released from hyaluronic acid hydrogel has a positive effect on early bone 
formation rate (chapter 2). In vitro studies nevertheless have shown that BP effects on osteogenic cells are 
highly dose dependent (Greiner, Kadow-Romacker et al. 2006; Orriss, Key et al. 2009). Therefore further 
dose-response studies with Zoledronate-loaded hydrogels are necessary to evaluate the dose dependency 
of the anti-resorptive effect on osteoclasts and, even more important, the positive effect on early bone 
formation.  
Finally, the insertion of non-load-bearing miniature screws in ovariectomized rats is a strong simplification 
of the real situation, which is the use of osteosynthesis systems in osteoporotic patients. Despite the very 
promising results in the rat study, more sophisticated studies with load-bearing implants in larger animal 
models will have to be performed for a reliable prediction of the actual time course and range of action of 
the drug effect that can be expected in humans.  
5.4.2 Investigation of the Enhanced Early Bone Formation 
MicroCT-based dynamic histomorphometry enabled us to detect an enhancement of the early bone 
formation in our animal studies (chapter 2). This technique nevertheless cannot show how this process is 
driven on a cellular level. Therefore further in vivo studies with histology scheduled already shortly after 
implantation are needed to understand how Zoledronate released from hyaluronic acid hydrogels can 
influence early bone formation. Those histology-focused experiments are ideally combined with the above-
mentioned dose-response studies in order to get a comprehensive view of the Zoledronate effect on 
osteogenic cells in vivo.  
5.4.3 Investigation of the in vivo Hydrogel Mineralization 
One very interesting aspect that was detected in the frame of this thesis but unfortunately could not be 
investigated more in detail is the rapid in vivo mineralization of the hyaluronic acid hydrogel in the 
presence of HA nanoparticles (chapter 3). It is well described in the literature that hydrogel can mineralize 
when calcium phosphate is added as nucleation points (Gkioni, Leeuwenburgh et al. 2010), but we could 
not find any studies reporting a mineralization of the gel with similar density than bone after 10 days of 
implantation. Even a group that used BP-bound calcium phosphate-containing hyaluronic acid hydrogels for 
bone repair did not report any significant mineralization after 4 weeks of implantation (Nejadnik, Yang et al. 
2014). Again, in vivo studies with histology scheduled at early time points have to be performed to 
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understand the mineralization processes and how they interfere with bone formation and resorption and 
the hydrogel degradation. For this purpose, a bone defect model should be chosen instead of the peri-
implant bone model, as the “in situ scaffold forming” hydrogel is a promising candidate for bone defect 
repair. Another very important aspect to investigate is the composition of the mineralized hydrogel as it 
could be done with energy-dispersive X-ray (EDX) spectroscopy and its mechanical properties by nano-
indentation. This way information about a possible augmentation or weakening of the bone by the 
presence of the mineralized granules can be gained. Furthermore, the in vitro mineralization capability of 
hydrogels should be tested for example by immersion of the gels in simulated body fluids. In vitro 
experiments would give a fast and easy possibility to identify critical parameters for the mineralization such 
as particle material, size, shape or concentration as well as the type, density and degradation profile of the 
hydrogel. Further analyses are also required to investigate the interaction between the hydrogel 
mineralization and the BP as well as the delivery of the drug and/or the drug loaded particles from the gel. 
5.4.4 Improvement of Implant Primary Stability 
One secondary objective of this thesis that finally could not be achieved was to prove that reinforcing the 
hydrogel with a sufficient amount of particles could improve the primary stability of the screws 
immediately after surgery. There are publications indicating that filling the space between the trabeculae 
can significantly improve pullout strength in human cancellous bone (Steeves, Stone et al. 2005). We 
followed this theory and performed pullout tests with either rat cadavers or artificial bone after application 
of hydrogels loaded with big amounts of hydroxyapatite or composite microspheres (annex). With both 
models, we could not confirm an enhancement of the force at pullout due to the application of the 
hydrogels. We concluded that both models were not appropriate to show this effect, as the cortex was very 
thick compared to the screw length in the rat cadaver model and the artificial polyurethane foam had no 
“cortex” at all and was simply too different from real bone. Further investigations should be done with 
either cadaveric human bone and if not available, bovine or ovine cadaveric bone. Complementary tests 
such as insertion and removal torque tests or resonance frequency analysis could also give a more global 
idea of the implant stability than a simple pullout test (Atsumi, Park et al. 2007). If it can be shown that a 
particle-BP-loaded hydrogel can improve both primary and secondary implant stability in osteoporotic 
bone, then a major step would have been taken towards the perfect implant fixation strategy that we 
described in chapter 5.1.  
5.4.5 The Path towards a Clinical Study 
Due to the industrial background of this thesis, all the research has to focus on a clinical study as milestone 
towards a final product. The performance of a clinical study requires the compliance with many rules and 
standards. First, all materials that are intended to be used in humans have to be certified for this purpose. 
The materials used for the experiments of this thesis were not all licensed for human use, therefore the 
next important step, before continuing with the above-described complementary studies, will be to find 
identical raw materials that are approved for implantation in humans. The next step will then be the 
Discussion and Perspectives 
109 
fabrication of the hydrogel that has to meet GMP standards. Therefore, a certified production site has to be 
found. Other important aspects are the sterilization, storage and application of the hydrogels. Suitable 
techniques, protocols and devices need to be developed and evaluated. All those procedures already have 
to be considered while continuing the research on this promising project to ensure a smooth transition to 
industry at the end.  
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Annex 
 Chronology of the Project: From Coating to Hydrogel A.1
A.1.1 Evaluation of a Drug Delivering Coating 
The initial idea of the CTI project behind this doctoral thesis was the development of a biodegradable, drug 
delivering polymer coating based on a published technique (Greiner, Wildemann et al. 2008; Back, Pauly et 
al. 2012). Different biodegradable polylactides (PLLAs) or polylactide-co-glycolides (PLGAs) (Resomer® R 
203 S / RG 756 / LR 706 S, Evonik Industries AG, Essen, Germany) were tested for this purpose. The 
polymers were dissolved in different solvents and applied to titanium or stainless steel bone screws 
(Stryker Trauma, Selzach, Switzerland) via a dip-coating process. After several pilot studies, we were facing 
two major issues with this technique. First, no suitable solvent could be found that can dilute both the 
biodegradable polymers and the Zoledronate, the bisphosphonate used for this project. As a result, a 
uniform distribution of the drug in the coating was not possible. The second problem was the insufficient 
abrasion resistance of the coating as it could be shown with screw-in tests in artificial bones (Sawbones 
1522-02, Vashon Islands, WA, US) (Figure A.1). 
 
Figure A.1:   Titanium cancellous bone screw coated with a polylactide (Resomer® R 203 H) directly after dip-coating (A), while 
being inserted in artificial bone (B), and after removal from the artificial bone (C). Scanning electron microscope image of the 
residues of a Resomer® R 203 coating containing hydroxyapatite nanoparticles after insertion in artificial bone (D). 
Extended dilution tests with numerous solvents (ethyl acetate, acetone, chloroform, DMSO and mixtures 
thereof) were performed to find a suitable solvent for polymer and drug. They revealed that Zoledronate is 
only soluble in water up to a concentration of around 3 mg/ml and in basic aqueous solutions with higher 
concentrations. None of the tested solvents was able to dissolve the drug. Consequently, we changed the 
strategy and used different water-soluble polyvinyl alcohols (PVA, art.-nr. 363138 / 363138, Sigma-Aldrich, 
MO, St. Louis, US) to integrate the drug. First abrasion tests showed that this polymer is even less resistant 
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than the PLLAs/PLGAs. Therefore we applied a layer of PVA incorporating the drug under a layer of PLLA, a 
combination that showed still a poor abrasion resistance. Different strategies were tested to enhance the 
adhesion of the coating to the screws. The screws were pre-treated with either hydrofluoric acid etching or 
a silanization to improve the polymer attachment to the metal surface. A second approach attempted to 
reinforce the polymer with hydroxyapatite nanoparticles (art.-nr. 677418, Sigma-Aldrich, St. Louis, MO, 
USA) that acted at the same time as a drug carrier and helped to circumvent the solvent issue. None of the 
tested techniques could significantly improve the abrasion resistance of the coating; therefore, we 
switched to a new approach for the drug delivery system. 
A.1.2 Evaluation of a Solid Drug Delivering Bone Plug 
As we were not able to attach the drug delivery system on the bone screws, we investigated the possibility 
of separating screw and drug delivery system and to develop a drug releasing screw anchor that is inserted 
in the predrilled hole before screw insertion. Tube-shaped prototypes were first produced from 
hydroxyapatite-polymer microspheres formed with a solvent evaporation technique (Kofron, Cooper et al. 
2007). The Zoledronate was loaded on the hydroxyapatite by a simple absorption. The microspheres were 
heat sintered to tubular structures (Figure A.2 A). First tests with artificial bone looked promising (Figure 
A.2 B) and first pullout tests demonstrated a gain in screw fixation of up to 15% when using this “bone 
plugs”. Further tests with a different Sawbone type with higher porosity and a structure more similar to 
human bone, however, revealed serious difficulties to insert the screw in the compact plug. Consequently, 
the strategy was changed once more and the microspheres were inserted in a hydrogel matrix (first cross-
linked PVA, later hyaluronic acid) instead of sintering them. This approach helped to circumvent problems 
with the insertion of the material in the hole, as the new material could be injected and facilitated 
significantly the penetration with the screw. Nevertheless, as mentioned in the discussion, we could not 
show an improved implant fixation with this approach neither with the Sawbone model nor with a rat 
cadaveric model. 
 
Figure A.2:   Bone plugs formed by heat sintering of hydroxyapatite-polylactide-microspheres (A), implanted with a cancellous bone 
screw in artificial bone (B). 
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 Hollow Hydroxyapatite-Polylactide Microspheres A.2
The above-mentioned composite microspheres were produced by diluting 15% of biodegradable PDLLA 
(Resomer® R 203 S, Evonik Industries AG, Essen, Germany) in chloroform (Sigma-Aldrich, St. Louis, MO, 
USA). Hydroxyapatite-nanoparticles with a diameter of less than 200 nm (art-nr. 677418, Sigma-Aldrich, St. 
Louis, MO, USA) were added to the solution with a ratio polymer/HA of 3:1. The resulting dispersion was 
poured into a 1% aqueous PVA solution (Mowiol® 8-88, Sigma-Aldrich, MO, St. Louis, US) under continuous 
stirring at 650 rpm with an overhead stirrer (Heidolph RZR 2020, Schwabach, Germany). After mechanical 
stirring for 15 h, the microspheres were removed from the PVA solution with filter paper, rinsed with bi-
distilled water and dried. The microspheres were fractioned with sieves into 3 groups of 45-100 µm, 100-
300 µm and 300-500 µm. 
A close inspection of the microspheres with microCT and SEM revealed that they are hollow (Figure A.3). 
This is a great advantage for their use in bone augmentation, as their large surface to volume ratio will 
speed up the degradation of the spheres while giving room for new bone formation. We could also show 
that the hydroxyapatite particles are present mainly on the inner and outer surface of the spheres (Figure 
6:3) which enhances their biocompatibility and potential for osteoconduction. An in vivo pilot study with 
one rat showed already an excellent osteointegration of the microspheres.  
Further research will be necessary but the hollow microspheres seem to be a promising candidate for 
reinforcing the drug-loaded hydrogels presented in this PhD thesis. 
 
Figure A.3:   Scanning electron microscope images of the hollow polylactide-hydroxyapatite composite microspheres with 
diameters ranging from 45-100 µm. They were fabricated via a solvent-evaporation technique. 
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